University of Missouri, St. Louis

IRL @ UMSL
Dissertations

UMSL Graduate Works

11-10-2017

Interactions Between Amyloid-beta and Microglial Cells
Lisa Gouwens
University of Missouri-St. Louis, lkpbn7@mail.umsl.edu

Follow this and additional works at: https://irl.umsl.edu/dissertation
Part of the Other Chemistry Commons

Recommended Citation
Gouwens, Lisa, "Interactions Between Amyloid-beta and Microglial Cells" (2017). Dissertations. 710.
https://irl.umsl.edu/dissertation/710

This Dissertation is brought to you for free and open access by the UMSL Graduate Works at IRL @ UMSL. It has
been accepted for inclusion in Dissertations by an authorized administrator of IRL @ UMSL. For more information,
please contact marvinh@umsl.edu.

INTERACTIONS BETWEEN AMYLOID-BETA AND MICROGLIAL CELLS
by
Lisa K. Gouwens
MS, Biochemistry & Biotechnology, University of Missouri-St. Louis, 2011
MEd, Secondary Education, University of Arkansas-Monticello, 2001
BS, Biology, University of Arkansas-Monticello, 1998

A Dissertation
Submitted to the Graduate School
of the
University of Missouri – Saint Louis
In partial fulfillment of the requirements for the degree of
Doctor of Philosophy
in
Chemistry
with an emphasis in Biochemistry
December 2017
University of Missouri – Saint Louis
Saint Louis, Missouri
Advisory Committee
Michael R. Nichols, PhD (Chairperson)
Cynthia M. Dupureur, PhD
Wesley R. Harris, PhD
Bethany K. Zolman, PhD

for
Willis Eugene Gouwens
Robert Veld Gouwens
Donald Lee Gouwens
and their families

ii

ACKNOWLEDGEMENTS
None of this would be possible without my advisor, Dr. Michael Nichols. I’ve
been around UMSL for a long time, therefore I appreciate your limitless patience. Thank
you for being a great teacher and mentor.
Members of the advisory committee, Drs. Dupureur, Harris, and Zolman, have all
taught courses in which I was a student. In those classrooms, I grew to respect and admire
you. I’m so grateful to you all for being part of my committee. In addition, I treasure the
mentoring from Dr. Dupureur as we worked together in the biochemistry teaching lab.
Many thanks!
What a privilege it’s been to work with everyone in the Nichols Lab. Geeta,
Shana, and Kelley, you were there in my first year and I thought I’d never know as much
as you all about Ab. Priyanka, you were a longsuffering partner in biochemistry lab and
my first friend at UMSL. Sanjib, we discovered that the third decimal place is important
when betting a beer on who has the best R2 value on a standard curve. Ben, I’ll always
remember your epic skills with Photoshop. Mudar and Nathan, microvesicles are nearly
invisible, and difficult to work with, but you persevered. Victoria and Fatima, I truly
enjoyed our time in the Golden Age of the lab. Nyasha, together we learned that food in
certain hotel restaurants can be delicious but is ridiculously overpriced. Next time, let’s
just order pizza.

iii

I would also like to thank Dr. David Osborn of the Microscope Imaging and
Spectroscopy Technology Lab at UMSL. Your help with imaging Ab and microvesicles
was invaluable and I enjoyed working with you.
Throughout my life I’ve been blessed with excellent science teachers, starting
with Ms Gifford in 4th Grade at St. Anne Elementary. Going to school in the evening
seemed like a silly idea until I saw the moon and stars through a telescope. Thank you for
showing me the beauty of the universe. Science got hold of me for good when I learned
about photosynthesis in high school biology class; thank you, Mr. Kelly. At UAM, Dr.
Eric Sundell, Dr. Walt Godwin, and Dr. Morris Bramlett were instrumental in
demonstrating both how to conduct science and how to teach.
As for my family, it would take countless pages to recount all of the joy each of
you brings into my life. I love you. Your support and encouragement have sustained me
during this journey. Thank you!

iv

TABLE OF CONTENTS

ACKNOWLEDGEMENTS ........................................................................................................ iii
LIST OF TABLES ......................................................................................................................vii
LIST OF FIGURES .................................................................................................................. viii
LIST OF ABBREVIATIONS ..................................................................................................... ix
ABSTRACT ................................................................................................................................. xi
CHAPTER 1: INTRODUCTION ............................................................................................... 1
1.1 Alzheimer’s disease overview .................................................................................. 1
1.2 Amyloid beta 42 (Ab42) ........................................................................................... 2
1.3 Microglia ................................................................................................................... 6
1.3.1 Inflammation and microglia ............................................................................................................ 6
1.3.2 Cellular uptake of extracellular material ................................................................................... 8
1.3.3 Internal trafficking of material in microglia .......................................................................... 10
1.3.4 Microglial P2X7 receptors .............................................................................................................. 10

1.4 Microvesicles .......................................................................................................... 12
CHAPTER 2: METHODS ....................................................................................................... 15
2.1 Ab preparation ........................................................................................................ 15
2.1.1 Ab aliquot lyophilization................................................................................................................ 15
2.1.2 Preparation of Ab monomers, protofibrils, and fibrils ..................................................... 16
2.1.3 Fluorescent labeling of Ab ............................................................................................................. 16
2.1.4 Size exclusion chromatography (SEC) ..................................................................................... 20

2.2 Characterization of fluorescently labeled Ab ......................................................... 21
2.2.1 Fluorescence measurements ....................................................................................................... 21
2.2.2 Absorbance measurements .......................................................................................................... 23
2.2.3 Ab concentration calculations ..................................................................................................... 23
2.2.4 Electron microscopy ........................................................................................................................ 26
2.2.5 Dynamic light scattering ................................................................................................................ 28

2.3 Cell Culture ............................................................................................................. 32
2.3.1 BV-2 microglia culture .................................................................................................................... 32
2.3.2 Primary microglia isolation and culture ................................................................................. 33

2.4 Microglial AF488-Ab uptake experiments ............................................................. 34
2.4.1 Ab treatment for ELISA and confocal LSM analysis ........................................................... 34
2.4.2 Ab treatment for fluorescence plate reader and dot blot analysis .............................. 35
2.4.3 BV-2 microglia cell binding assay .............................................................................................. 36

2.5 Fluorescence quantitation for AF488-Ab-treated microglia .................................. 36
2.6 Immuno-detection of Ab and confocal microscopy ............................................... 39
2.6.1 Preparation of fixed cells for microscopy ............................................................................... 39
2.6.2 Confocal microscopy........................................................................................................................ 40

2.7 Immuno-dot blot ..................................................................................................... 42
2.8 ELISA ..................................................................................................................... 43
v

2.9 Microvesicle generation and isolation from BV-2 and primary microglia ............. 44
2.10 Fluorescence measurements of microvesicles ...................................................... 46
2.11 Confocal LSM imaging of microvesicles ............................................................. 46
2.12 Preparation of microvesicles for resin-embedded TEM ....................................... 47
2.13 BCA Assay ........................................................................................................... 48
CHAPTER 3: Ab INTERACTIONS WITH MICROGLIAL CELL SURFACES................. 49
3.1 Binding of distinct Ab conformers ......................................................................... 49
3.2 Time-dependence of Ab42 interaction with BV-2 cell surfaces ............................ 53
3.3 Effect of temperature on Ab42 binding to BV-2 cell surfaces ............................... 55
3.4 Effect of Ab42 concentration on binding to BV-2 cell surfaces ............................ 57
3.5 Correlation of Ab42 binding and BV-2 activation ................................................. 60
CHAPTER 4: SELECTIVE INTERNALIZATION OF Ab BY MICROGLIA ..................... 64
4.1 Comparison of unlabeled and fluorescently-labeled Ab42 monomer, protofibril,
and fibril interactions with BV-2 and primary microglia ...................................... 65
4.2 Time dependent internalization of AF488-Ab by primary microglia..................... 67
4.3 Effect of AF488-Ab concentration on primary microglial uptake ......................... 72
4.4 Non-saturable Ab uptake in primary microglia ...................................................... 73
4.5 Colocalization analysis of AF488-Ab with lysosomes........................................... 80
CHAPTER 5: MICROVESICLES ............................................................................................ 86
5.1 Microvesicles from BV-2 microglia ....................................................................... 86
5.1.1. A488-Annexin V visualization of BV-2 microvesicles ...................................................... 87
5.1.2. Bicinchoninic acid protein assay of BV-2 microvesicles ................................................. 88
5.1.3. Dynamic light scattering characterization of BV-2 microvesicles .............................. 91
5.1.4. Transmission electron microscopy of resin-embedded BV-2 microvesicles ......... 93
5.1.5 Tracking microvesicles with NBD C6-HPC fluorescence ................................................. 96

5.2 Characterization of microvesicles from primary microglia .................................... 99
5.3 Overall conclusion ................................................................................................ 101
BIBLIOGRAPHY .................................................................................................................... 103
VITA ......................................................................................................................................... 114

vi

LIST OF TABLES

CHAPTER 2 METHODS
2.1 Stoichiometry of protofibril and monomer peak fractions ....................................27
CHAPTER 3 Ab INTERACTIONS WITH MICROGLIAL CELL SURFACES
3.1 Ab internalization in BV-2 and other cell lines .....................................................58
CHAPTER 4 AF488-Ab INTERNALIZATION BY PRIMARY MICROGLIA
4.1 Primary microglia internalization of Ab experiments ...........................................74
4.2 Lysosome colocalization experiments ...................................................................82

vii

LIST OF FIGURES
CHAPTER 1 INTRODUCTION
1.1 Ab and APP .............................................................................................................3
1.2 Ab aggregation.........................................................................................................4
1.3 Microglial activation and cytokine production ........................................................7
1.4 Mammalian cell uptake ............................................................................................9
1.5 Lysosomes..............................................................................................................11
1.6 Microvesicles .........................................................................................................13
CHAPTER 2 METHODS
2.1 Structure of Alexa Fluor® 488 tetrafluorophenyl ester .........................................18
2.2 Labeling reaction mechanism for Ab and amine-reactive AF488-TFP.................19
2.3 Representative UV trace for SEC elution overlaid with fluorescence
measurements of fractions .....................................................................................22
2.4 AF488 absorbs at 280 nm ......................................................................................24
2.5 Comparison of UV-Vis absorbance measurement methods ..................................25
2.6 Transmission electron micrographs of unlabeled Ab and AF488-Ab42 ...............29
2.7 Dynamic light scattering ........................................................................................31
2.8 Plate reader fluorescence, AF488-Ab ....................................................................38
2.9 Confocal laser scanning microscopy .....................................................................41
CHAPTER 3 Ab INTERACTIONS WITH BV-2 MICROGLIAL CELL SURFACES
3.1 Binding of distinct species of Ab...........................................................................50
3.2 Time dependence of surface binding to BV-2 microglia .......................................54
3.3 Temperature effect on surface binding to BV-2 microglia ....................................56
3.4 Ab42 concentration dependence of cytokine secretion by BV-2 microglia ..........61
3.5 Correlation of Ab42 binding and BV-2 cell activation .........................................63
CHAPTER 4 AF488-Ab INTERNALIZATION BY PRIMARY MICROGLIA
4.1 AF488 fluorophore does not affect primary microglial interaction with Ab.........66
4.2 Internalization of AF488-Ab by primary microglia ..............................................68
4.3 Primary microglia take up AF488-Ab protofibrils, but not AF488-Ab monomers,
in a time dependent manner ...................................................................................71
4.4 Concentration dependent internalization of AF488-Ab by primary microglia .....77
4.5 Competition/saturation images and quantitation ...................................................79
4.6 Lysosome colocalization ........................................................................................85
CHAPTER 5 MICROVESICLES
5.1 AF488-Annexin V visualization of microvesicles from BV-2 cells .........................89
5.2 BCA assays ................................................................................................................91
5.3 Dynamic light scattering analysis of microvesicles ...................................................93
5.4 TEM of resin-embedded BV-2 microvesicles ...........................................................94
5.5 NBD C6-HPC fluorescence indicates the presence of microvesicles ........................97

viii

LIST OF ABBREVIATIONS

Ab42 – amyloid beta 1-42
aCSF – artificial cerebrospinal fluid
AD – Alzheimer’s disease
AF488 – Alexa Fluor® 488
AF488-Ab42 – Alexa Fluor® 488 amyloid beta 1-42
AF488-TFP – Alexa Fluor® 488 tetrafluorophenyl ester
APP – amyloid precursor protein
BCA – bicinchoninic acid
Bz-ATP – 2’(3’)-O-(4-Benzoylbenzoyl)adenosine 5’-triphosphate triethylammonium salt
CSF – cerebrospinal fluid
DAMP – danger associated molecular pattern
DLS – dynamic light scattering
DMEM – Dulbecco’s modified Eagle’s medium
ELISA – enzyme-linked immunosorbent assay
FITC – fluorescein isothiocyanate
IL-1b – interleukin 1b
MALS – multi-angle light scattering
MIST – microscope imaging and spectroscopy technology
MV – microvesicle

ix

NBD C6-HPC – 2-(6-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)hexanoyl-1hexadecanoyl-sn-glycero-3-phosphocholine
PAMP – pathogen associated molecular pattern
PC – phosphatidylcholine
PRR – pattern recognition receptor
PS – phosphatidylserine
RH – hydrodynamic radius
SEC – size exclusion chromatography
TEM – transmission electron microscopy
ThT – thioflavin T
TLR – toll-like receptor
TNFa – tumor necrosis factor a
UV – ultraviolet
ZEN – Zeiss Efficient Navigation

x

ABSTRACT

Gouwens, Lisa K. Ph.D., University of Missouri-St. Louis, December 2017. Interactions
between amyloid-beta and microglial cells. Major Professor: Michael R. Nichols.

Alzheimer’s disease (AD), the most common cause of dementia, is a
neurodegenerative condition characterized by loss of memory and intellectual abilities.
Intracellular plaques of aggregated amyloid-beta (Ab) protein are a well-known
pathology associated with AD. Although symptoms usually appear late in life, the
accumulation of Ab begins decades earlier and causes activation of microglia, the brain’s
immune cells. The ensuing inflammation contributes significantly to neurodegeneration.
Determination of the particular form of Ab that causes the most damage in the brain is
one of the major questions in the AD field. My research focused on the interactions of
microglia with monomers, protofibrils, and fibrils of Ab. I found that protofibrils, not
monomers or fibrils, bind to microglial surfaces, and I confirmed earlier reports that
protofibrils elicit a proinflammatory response from microglia. These results were
consistent regardless of changing conditions such as temperature, incubation time and Ab
concentrations.
Another aspect of my research was to investigate how microglia internalize
different forms of Ab. The distinction between monomers and protofibrils may have
xi

physiological significance in AD, yet there are few reports in the literature in which these
two forms of Ab are examined separately. Monomers and protofibrils were carefully
separated by size exclusion chromatography before cell treatments, which sets apart this
work from research done in other labs. Multiple conditions and strategies, including a
novel quantitation method for internalized Ab, demonstrated that microglia favor
internalization of protofibrils over monomers. Further experiments determined that
microglia are capable of internalizing protofibrils in high amounts without degradation. A
significant amount of Ab protofibrils remain in the cytoplasm and are not routed to
lysosomes, contradicting reports in the literature.
A third research objective involves the study of microvesicles released from
microglia. Microvesicles may have a role in AD by transporting Ab within the brain. I
conducted experiments in which microglia were stimulated to produce microvesicles, and
carried out assays to both confirm the presence of and visualize microvesicles. The
studies described here contribute to the understanding of the interactions between
microglia and Ab, potentially leading to a possible treatment or cure for AD.

xii

CHAPTER 1: INTRODUCTION
1.1 Alzheimer’s disease overview
As the number of people affected by Alzheimer’s disease (AD) continues to grow,
investigations into the basic biochemistry and cellular aspects of this neurodegenerative
disorder continue. Ultimately fatal, AD currently afflicts over 5 million people in the
United States, and this number is expected to increase to 16 million by 2050, according to
the Alzheimer’s Organization (March 2015 Fact Sheet). Tens of millions of people
worldwide are victims of AD (World Health Organization), and this tally is expected to
triple by 2050.
In most cases, AD manifests itself late in life, with loss of memory, difficulty
recalling new information, and loss of intellectual abilities. These symptoms were
associated with extracellular plaques of amyloid beta (Ab) and intraneuronal tau tangles,
first described by Dr. Alois Alzheimer in 1907 (Stelzmann, et al., 1995). Yet, the buildup
of Ab and tau begins decades before the manifestation of symptoms (Selkoe, 2011).
While tau is an integral component of the disease process, the aggregation of Ab between
brain cells precedes the formation of tau tangles within neurons (Selkoe and Hardy,
2016). What follows is dysfunction in a variety of cell types in the brain (vascular cells,
pericytes, astrocytes, oligodendrocytes, and neurons), including Ab clearance dysfunction
and inflammation in microglia (discussed below), as a response to or consequence of Ab
build-up in the brain (De Strooper and Karran, 2016).
1

1.2 Amyloid beta 42 (Ab42)
Ab is a peptide that is derived from a large transmembrane protein, up to 770
amino acids in length, known as amyloid precursor protein [APP; (Wilkins and
Swerdlow, 2016)]. The functions of APP include neuronal development, intracellular
transport, signaling, and homeostasis (van der Kant and Goldstein, 2015). Figure 1.1A
shows a schematic for APP with labels for the transmembrane domain as well as the sites
of cleavage for a-, b, and g-secretases (Selkoe, 2011). Sequential cleavage by b-secretase
then g-secretase results in the formation of the Ab peptide, which can be 36-42 amino
acids in length (van der Kant and Goldstein, 2015). It is the 42-residue peptide that
aggregates, causing the well-known pathology of intercellular plaques in AD (Jarrett, et
al., 1993).
The Ab42 monomer is a disordered peptide with a molecular weight of 4.514
kDa. The amino acid sequence, shown in Figure 1.1B, is color-coded to show residue
properties. The aggregation process shown in Figure 1.2 begins during the rate-limiting
nucleation phase and is followed by assembly of the aggregation nuclei via non-covalent
interactions (Jarrett, et al., 1993) to form soluble dimers, trimers and so on, which results
in a solution of polydisperse soluble oligomers (Bitan, et al., 2003; Kayed, et al., 2003;
Mittag, et al., 2014). Nucleation dependent polymerization is characterized by a lag
phase, which is then followed by rapid aggregation (Jarrett and Lansbury, 1993).
Subsequent steps lead to the formation of soluble protofibrils (Harper, et al., 1999;
Mittag, et al., 2014; Walsh, et al., 1997, 1999) and insoluble fibrils(Harper, et al., 1997).
The protofibril-to-fibril conversion can occur via monomer addition to protofibril ends,
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A

B

Figure 1.1. Ab and APP. (A) APP processing (Selkoe, 2011) (B) Ab42 schematic with
one letter abbreviations for residues.

3

Figure 1.2 Ab aggregation. Monomers are disordered peptides. The pathways which do
not lead to aggregation (annulus, dodecamer, and amylospheroid) are distinct from the
pathway which results in fibril aggregation via protofibrils. From Figure 1,
Roychaudhuri, et al. (2009).
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the joining of protofibril tips to one another, and lateral association of protofibrils
(Harper, et al., 1999; Nichols, et al., 2002). Ab42 fibrils make up the dense cores of
intercellular plaques (Terry, et al., 1964) with soluble Ab on the periphery of the plaques
(Koffie, et al., 2009).
Protofibrils are fibril precursors (Harper, et al., 1997; Walsh, et al., 1997) that
have beta sheet structure (Nichols, et al., 2015; Walsh, et al., 1999). Though protofibrils
are not as stable as fibrils (Kheterpal, et al., 2003; Walsh, et al., 1999), they resemble
fibrils in thioflavin T (ThT) binding and circular dichroism (Walsh, et al., 1999).
Protofibril lengths have been reported as <200 nm (Walsh, et al., 1997), and our
measurements of protofibril lengths have been consistent with that, ranging from 50 ± 16
nm to 78 ± 35 nm (Nichols, et al., 2015; Paranjape, et al., 2012). Reported diameters for
protofibrils vary from 4-6 nm (Harper, et al., 1997). The hydrodynamic radius (RH) of
protofibrils, measured by dynamic light scattering (DLS), has been reported to be 10-50
nm (Walsh, et al., 1997), and our measurements of 21± 6 nm (Paranjape, et al., 2012),
21.9 ± 4.0 nm (Paranjape, Terrill, and Gouwens, et al., 2013), and 23.6 ± 3.3 nm
(Nichols, et al., 2015) fall into that range. Analyzed by SEC with in line multi-angle light
scattering (MALS), protofibril molecular weights (MW) ranged from 200-2600 kDa, with
an average of 884±302 kDa, (Nichols, et al., 2015). We are particularly interested in
protofibrils because they have been shown to be toxic to neurons (Walsh, et al., 1999),
disrupt ion channels (Ye, et al., 2003), and inhibit long-term potentiation in the
hippocampus (O'Nuallain, et al., 2010). Additionally, results from our lab have shown
that the soluble protofibrils of Ab42 are responsible for the activation of macrophages
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and microglia that results in the production of cytokines (Ajit, et al., 2009; Paranjape, et
al., 2012; Paranjape, Terrill, and Gouwens, 2013).
1.3 Microglia
During early embryonic development, hematopoietic stem cells give rise to
microglial cells, which migrate to the central nervous system [CNS, (Ransohoff and
Cardona, 2010)]. Microglia are macrophages in the CNS, shaping neural circuits during
development and throughout life (Banati and Graeber, 1994; Frost and Schafer, 2016; Ji,
et al., 2013); Microglia are also involved in surveillance of the intercellular space,
cleaning up dead cells and debris, and responding to threats (Kettenmann, et al., 2011).
Activated microglia can be found near plaques in AD brain (McGeer, et al., 1987; MeyerLuehmann, et al., 2008), along with proinflammatory cytokines (Dickson, et al., 1993),
and have been observed accumulating rapidly around new plaques (Meyer-Luehmann, et
al., 2008).
1.3.1 Inflammation and microglia
The microglial inflammatory response, illustrated in Figure 1.3, is implicated in
several CNS diseases (Frankola, et al., 2011). Though labeled “resting”, microglia use
their many branches to actively read their surroundings (Kettenmann, et al., 2011). The
exogenous signals that initiate inflammatory pathways, such as microbial infection, are
pathogen-associated molecular patterns (PAMPs), which are molecular patterns not
present in the host tissues (Tang, et al., 2012). Pattern recognition receptors (PRRs) such
as toll like receptors (TLRs) sense and respond to PAMPs, initiating cell signaling
pathways in an attempt to mitigate the problem (Tang, et al., 2012). Similarly, when they
sense danger-associated molecular patterns (DAMPS), which are endogenous signals
6

Figure 1.3 Microglial activation and TNFa production (Frankola, et al., 2011).
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indicating injury not related to an infection (Tang, et al., 2012), such as Ab, microglia
become activated and produce proinflammatory cytokines, including tumor necrosis
factor a (TNFa) and interleukin-1b (IL-1b) (Patel, et al., 2005). Chronic inflammation is
thought to be partly responsible for neurodegeneration in AD, having a significant impact
before symptoms appear (McGeer and McGeer, 1998). A variety of microglial receptors
are involved in AD pathology. The receptors known to elicit proinflammatory responses
when stimulated by fibrillar Ab include a complex of CD36, a6b1-integrin, and integrin
associated CD47 (Bamberger, et al., 2003); CD14 (Fassbender, et al., 2004); toll-like
receptor (TLR) 2 and TLR4 (Reed-Geaghan, et al., 2009); CD36 (El Khoury, et al., 2003;
Moore, et al., 2002); and a CD36-TLR4-TLR6 complex (Stewart, et al., 2010). Others
include complement receptors, Fc receptors that bind the constant domain of
immunoglobin, formyl peptide receptors 1 and 2, receptor for advanced glycation end
products, nod-like receptor protein, CD33, scavenger receptor A, and triggering receptor
expressed by myeloid cells (Doens and Fernández, 2014).
1.3.2 Cellular uptake of extracellular material
Mammalian cells ingest materials by way of phagocytosis or pinocytosis. Figure
1.4 provides an illustration of general mammalian cell uptake. Only pathogens and large
particles are ingested through phagocytosis, which requires receptors. Of the five forms
of pinocytosis, macropinocytosis does not require receptors. In this type of
internalization, cell surface membranes produce waves, or ruffles, that extend into the
extracellular space and then reconnect with the plasma membrane, bringing into the cell
any particles that are in the surrounding medium (Conner and Schmid, 2003).
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Figure 1.4 Mammalian cell uptake (Conner and Schmid, 2003).
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Receptors known to be involved with Ab-microglial uptake of extracellular
material include scavenger receptors (Paresce, et al., 1996); a complex of CD36, a6b1integrin, and CD47 (Koenigsknecht and Landreth, 2004); complement receptor 3 (CR3,
Mac-1) signal regulatory protein b1 (SIRPb1) (Gaikwad, et al., 2009); and P2Y4 (Li, et
al., 2013). Surface receptors such as toll like receptors (TLRs) have been shown to be
involved in the activation of microglia as they interact with Ab42 (reviewed in Su, et al.,
2015). Mandrekar, et al. (2009) demonstrated that microglia take up soluble Ab via fluidphase macropinocytosis, which is not mediated by receptors.
1.3.3 Internal trafficking of material in microglia
Most cells have lysosomes, acidic organelles that break down misfolded proteins
and other unwanted material. Material can be routed to lysosomes through the pathways
illustrated in Figure 1.5. Once ingested substances are internalized, they become part of a
vesicle known as an early endosome (EE), which develops into a late endosome
(LE)/multivesicular body (MVB). An alternative is that the LE becomes a recycling
endosome (RE) which moves the material out of the cell. Some material will become part
of the endolysosome (EL), which is formed when the LE/MVB fuses with a lysosome.
Normally, unwanted material would be degraded within the acidic lysosome. As
discussed in Chapter 4, this is not always the case for microglia interacting with Ab.
1.3.4 Microglial P2X7 receptors
Characterized in 1996 (Surprenant, et al., 1996), P2X7 receptors are found in all
types of immune cells, including microglia (Burnstock and Knight, 2004; Chen and
Brosnan, 2006). With regard to AD, the presence of P2X7 receptors is increased in
10

Figure 1.5 Lysosomes (Luzio, et al., 2014)
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microglia near plaques in a mouse model of AD (Parvathenani, et al., 2003) and in
human AD brains (McLarnon, et al., 2006; Takenouchi, et al., 2010). P2X7 receptors
respond to ATP at millimolar concentrations, and at even lower concentrations for the
agonist 2’,3’-(benzoyl-4-benzoyl)-ATP (BzATP) (Surprenant, et al., 1996). In response
to ATP and/or LPS, microglia release inflammatory cytokines such as TNFa (Hide, et al.,
2000) and IL-1b (Brough, et al., 2002; Ferrari, et al., 1997; Rampe, et al., 2004). The
cytokine release has been shown to occur through microvesicle production (Bianco, et al.,
2005).
1.4 Microvesicles
An important aspect of intercellular communication is the release of membranebound packets of cytoplasm from cells (Budnik, et al., 2016). These extracellular vesicles
can be categorized by size and origin into two groups: exosomes are 30-100 nm in
diameter and part of larger multi-vesicular bodies, and microvesicles are 100-1000 nm in
diameter and form as buds from the cell surface (Budnik, et al., 2016). As shown in
Figure 1.6 (top), microvesicles are complex, having varied receptors and cargoes. The
budding process is also illustrated in Figure 1.6 (bottom), and of special interest for my
work is the externalization of phosphatidylserine (PS), which can be used in experiments
to verify the presence of microvesicles.
Microvesicles have various roles outside of direct AD involvement. THP-1
monocytes, immune cells in the bloodstream, release IL-1b via microvesicles
(MacKenzie, et al., 2001). Microglia also release microvesicles carrying cytokines when
stimulated with ATP (Bianco, et al., 2005). In 2009, Bianco and colleagues demonstrated

12

Figure 1.6 Microvesicles. Top: Structure. Bottom: formation from plasma membrane.
Note the externalization of phosphatidylserine. (Hugel, et al., 2005)
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the release of microvesicles from astrocytes and further showed that the mechanism
proceeds through a p38 MAPK cascade and requires acid sphingomyelinase. Microgliato-neuron signaling was demonstrated by Antonucci, et al. (2012), and microvesicle
stimulation of neuronal activity was shown by Turola, et al. (2012). The usefulness of
microvesicles in identifying neuroinflammation caused by multiple sclerosis and
measuring reduction of neuroinflammation through treatment was reported by Verderio,
et al. (2012).
With regard to microvesicles in AD, and from microglia in particular, there are
interesting findings. Bianco, et al. (2005) demonstrated that microglia shed microvesicles
when stimulated with ATP, and that the microvesicles contain the cytokine IL-1b.
Microvesicles from microglia can interact with fibrillar Ab and convert it to a soluble and
more toxic Ab form (Joshi, et al., 2014). Studies of human cerebrospinal fluid revealed
that the combination of microvesicles and Ab42 is toxic to human brain cells and
contributes to the spread of neurodegeneration through the AD brain (Agosta, et al.,
2014). The effect of microglial microvesicles on Ab42 aggregation and the role of
microvesicles in Ab42 trafficking within and between cells are growing areas of research
emphasis. Chapter 5 describes the work done to connect microvesicle production with Ab
stimulation in microglia.

14

CHAPTER 2: METHODS
2.1 Ab preparation
The Ab42 peptide used in my experiments was supplied by the same group under
two different company names. They were known as the Large Scale Peptide Synthesis
Laboratory in the W.M. Keck Biotechnology Resource Laboratory, Yale School of
Medicine (Yale, New Haven, CT). In June, 2013, the lab ceased operation under that
name, and in May of 2014 began work as the ERI Amyloid Laboratory, LLC (ERI,
Oxford, CT). The ERI Amyloid Laboratory is our current Ab peptide supplier. Of the
seven labeled preparations, the first three were from Yale, and the last 4 were from ERI.
There were no significant differences between the peptide batches. The sequence and
purity of all Ab peptide shipments were confirmed by mass spectrometry at ERI.
2.1.1 Ab aliquot lyophilization
Ab42 was obtained in lyophilized form and stored at -20 °C. Nucleation of
amyloid proteins leads to rapid aggregation and occurs quickly in a concentrated solution
(Jarrett and Lansbury, 1992), so dissociating any pre-formed Ab seeds is necessary to
prevent aggregation. To prepare monomeric aliquots, the peptide was dissolved in 100%
hexafluoroisopropanol (HFIP) (Sigma-Aldrich, St. Louis) at 1 mM and separated into 1
mL aliquots in sterile, siliconized microcentrifuge tubes. The tubes were then left
uncovered, at room temperature, overnight in a fume hood to evaporate the HFIP. On the
following day, the aliquots were vacuum-centrifuged to remove any residual HFIP. A
15

thin film of Ab was deposited on the inside walls of the microcentrifuge tubes, which
were then stored in dessicant at -20 °C.
2.1.2 Preparation of Ab monomers, protofibrils, and fibrils
A modified (without glucose) artificial cerebrospinal fluid (aCSF) was used to
prepare Ab solutions. The composition of our aCSF is 15 mM NaHCO3, 1 mM Na2HPO4,
130 mM NaCl, 3 mM KCl, pH 7.8. This aCSF solution was designed to mimic the ionic
strength of cerebrospinal fluid and cell culture medium while leaving out the supplements
that might interfere with spectroscopy and retaining the cell compatibility of growth
medium (Paranjape, Terrill, and Gouwens, et al., 2013). The solution of Ab42 monomers
and protofibrils was prepared by dissolving lyophilized Ab42 (1 mg) in 50 mM NaOH to
yield a 2.5 mM Ab42 solution, which was then diluted to 250 µM Ab42 in prefiltered
(0.22 µm) artificial cerebrospinal fluid. To allow protofibril formation, the Ab42 solution
was incubated at room temperature for 30 min - 4 h. The wide range of incubation times
was necessary as some of the aliquots required more time to form soluble aggregates. At
this point, unlabeled Ab42 was purified by size exclusion chromatography (SEC) as
described in 2.1.4 below. Peptide to be fluorescently labeled underwent the procedure
described in 2.1.3. Fluorescently-labeled Ab4 fibrils were prepared by leaving monomer
preps at 4 °C for two or more weeks; usually fibrils form after two weeks.
2.1.3 Fluorescent labeling of Ab
In some experiments with microglia, I conducted immunofluorescence assays to
determine the location of Ab42 on or in treated cells (Paranjape, et al., 2012; Paranjape,
Terrill, and Gouwens 2013). However, direct labeling with a fluorophore is a more
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efficient method for tracking microglial interactions with Ab42. This strategy has been
used by many research groups (for example, Fu, et al., 2012; Halle, et al., 2008; Li, et al.,
2012; Liu, et al., 2010; Mandrekar, et al., 2009; Paresce, et al., 1997). Alexa Fluor® 488
carboxylic acid, 2,3,5,6-tetrafluorophenyl ester (AF488-TFP, Life Technologies) is an
amine-reactive fluorophore that has been used to label soluble oligomers of Ab42
(Jungbauer, et al., 2009). The structure of AF488-TFP is shown in Figure 2.1. In their
experiments, Jungbauer and colleagues compared oligomers labeled before aggregation
to oligomers labeled after aggregation. Their work showed that allowing the peptide to
aggregate before conducting the labeling experiment, rather than labeling monomers first
and allowing them to aggregate, produced soluble, labeled Ab oligomers that are most
similar to unlabeled Ab oligomers. Therefore, I used a solution containing both
monomers and protofibrils, prepared as described above, for the labeling reaction.
Attaching a fluorescent label directly to the peptide had several advantages. The
direct fluorescence meant that I could visualize Ab42 both on and in cells without the
risk of non-specific interactions between antibodies and non-target proteins. The strength
of the fluorescence allowed visualization of Ab42 even at low concentrations of 0.5, 1
and 2 µM. Less time was required for completing experiments, and I had the option of
imaging live cells.
There are three primary amine groups in the Ab42 monomer which can
potentially interact with AF488-TFP: lysine-16, lysine-28, and the N-terminus. Each of
these is a nucleophile that can attack the carbonyl carbon located between the
tetrafluorophenyl group and the fluorophore of A488-TFP. The reaction mechanism for
the Ab N-terminal amine is shown in Figure 2.2.
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Figure 2.1 Structure of Alexa Fluor ® 488 tetrafluorophenyl ester (Life Technologies).
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Figure 2.2 Labeling reaction mechanism for Ab and amine-reactive AF488-TFP. I drew
this mechanism using ChemDoodle® software (Version 7.0.1, iChemLabs.)
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The manufacturer’s protocol calls for dissolving the protein to be labeled in 1 mL
of sodium bicarbonate buffer pH 8.3, dissolving the dye in dimethylsulfoxide or
dimethylformamide at 10 mg/mL, and then combining the two solutions. A conversation
with an Invitrogen support technician confirmed that if the pH was 8.0 or higher, the
labeling reaction would proceed in our aCSF buffer. The NaOH/aCSF solution in which
the peptide was prepared has a pH of 8.2.
To conduct the labeling reaction, 500 µL of an Ab42 solution with both
protofibrils and monomers was added to 100 µg of AF488-TFP dry powder in the
original tube from the manufacturer, mixed gently by pipet, and transferred to a 1.8 mL
glass vial containing a 5-mm magnetic stir bar. A second 500 µL volume of Ab42
solution was added to the original tube to capture any remaining powder, then transferred
to the glass vial. The Ab/AF488-TFP mixture was gently stirred for 1 h at 25°C. After
stirring, the solution was transferred to a siliconized microcentrifuge tube prior to
chromatographic separation.
2.1.4 Size exclusion chromatography (SEC)
Before SEC, the AF488-Ab monomer+protofibril solution underwent
centrifugation at 17,000 x g for 10 minutes to pellet any non-soluble fibrils that may have
formed. Both unlabeled and fluorophore-labeled Ab42 centrifugation supernatants were
fractionated on a Tricorn Superdex 75 10/300 GL column (GE Healthcare) using an
AKTA FPLC system (GE Healthcare). Prior to injection of the Ab42, the Superdex 75
column was coated with sterile bovine serum albumin (Sigma) to prevent any nonspecific binding of Ab42 to the column matrix. 1 mL of the sample was loaded, either
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Ab42 or AF488-Ab was eluted at 0.5 mL min-1 in aCSF, and 0.5 mL fractions were
collected and immediately placed on ice. Elution was monitored in-line by UV
absorbance (A280), and concentrations of unlabeled Ab42 were determined from these
absorbance values. A representative UV trace, combined with fraction fluorescence
measurements, for AF488-Ab is shown in Figure 2.3. AF488-Ab42 concentrations were
determined as described below in Section 2.2.3. Shana Terrill-Usery, Sanjib Karki, Ben
Colvin, and Nyasha Makoni all assisted me with SEC.
2.2 Characterization of fluorescently labeled Ab
2.2.1 Fluorescence measurements
AF488 has a maximum emission at 525 nm (Life Technologies). Measuring the
fluorescence of each 0.5 mL fraction which can be used to confirm labeling success. If
the fluorescence of the fractions lines up with the peaks on the inline trace then it is
reasonable to assume that the labeling was successful. AF488-labeled Ab42 fluorescence
in SEC fractions was determined using a Cary Eclipse fluorescence spectrophotometer.
Emission scans of 500-600 nm were obtained with an excitation wavelength of 495 nm.
The resulting curves were integrated from 505-550 nm to produce relative fluorescence
units (RFU), shown in Figure 2.3 as red circles. The integrated fraction fluorescence
values align well with the SEC trace peaks, which confirms the association of the
fluorophore with the peptide.
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Figure 2.3 Representative UV trace for SEC elution overlaid with fluorescence
measurements of fractions. SEC trace (blue line) and fraction fluorescence (red circles)
showing peaks for protofibrils, monomers, and unincorporated AF488-TFP (AF dye).
(Gouwens, et al., 2016)
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2.2.2 Absorbance measurements
An inline UV trace identified the fractions containing Ab42. For unlabeled Ab42,
this trace is used to determine the concentration of peptide in each fraction. However, the
inline UV overvalued the concentrations in each fraction of AF488-Ab because the
AF488 fluorophore absorbs at 280 nm. Manual measurements of UV absorbance were
taken to use in calculations. AF488-Ab chromatography samples were scanned from 600
to 220 nm on a Cary 50 (Varian) UV/Visible spectrophotometer. Figure 2.4 contains a
representative scan of a fraction containing unincorporated AF488-TFP in aCSF that is
typical of the seven labeled preps. The large peak near 500 nm is due to the fluorophore,
Ab42 has no absorbance at those wavelengths. A low amount of absorbance is visible at
280 nm (0.1 AU), and because of that I needed to calculate AF488-Ab concentrations
(see Section 2.2.3). Confirmation that using the manual absorbance measurements for
calculations would be accurate came from comparing the A280 manual measurements to
the inline UV absorbance, as is shown in Figure 2.5. Absorbance measurements of peak
fractions (red circles) of protofibril, monomer, and unreacted AF488-TFP all fall on the
line obtained from the inline trace (blue line). This indicates that both methods of
assessing UV absorbance agree.
2.2.3 Ab concentration calculations
Since Ab42 and the AF488 label both contribute to total absorbance (A280, tot),
AF488-Ab42 concentrations were obtained after subtraction of the fluorophore
absorbance at 280 nm (A280, AF488) from A280, tot. The contribution of AF488 to A280, tot is
described by the relationship A280, AF488 = A494, AF488 x 0.11, where A494, AF488 is the
absorbance of the fluorophore at 494 nm (Life Technologies). Concentrations of AF48823
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Figure 2.4 AF488 absorbs at 280 nm. The large peak at 494 nm is due to the
unconjugated AF488 fluorophore. The absorbance at 280 nm is equal to 11% of the
absorbance at 494 nm.
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Figure 2.5 Comparison of UV-Vis absorbance measurement methods. Absorbance values
at 280 nm measured by SEC inline UV (blue line) and manual UV spectrophotometry of
0.5 mL fractions (red circles). Representative data from one of the seven labeled preps.
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Ab in sample preparations were determined using A494, AF488 and A280, tot from the
absorbance scans and the following calculation derived from Beer’s Law (A = e l c):
CAF488-Ab = [A280, tot – (A494, AF488 x 0.11)] ÷ [e280, Ab x l]

(Equation 1)

where l is the path length (1 cm) and e280, Ab is the extinction coefficient at 280 nm for Ab
1450 M-1 cm-1 (Nichols, et al., 2002). Unincorporated AF488-TFP concentrations were
determined using an extinction coefficient at 494 nm of 71,000 M-1 cm-1 (Life
Technologies). The AF488:Ab42 stoichiometry was then obtained. Table 2.1 provides a
summary of the labeling stoichiometry of peak protofibril and monomer fractions. In
protofibrils, lysine-16, lysine-28, and some N-termini may not be accessible to the
fluorophore, so it was expected that there would be a lower labeling stoichiometry for
protofibrils than monomers. For the seven AF488-Ab42 preparations used in my
experiments, the average AF488:Ab42 ratio was 0.14 ± 0.03 for protofibrils, and 0.50 ±
0.08 for monomers. The three-fold higher stoichiometry of labeling for monomers was
meaningful for data interpretation.
2.2.4 Electron microscopy
SEC-purified Ab solutions, both labeled with Alexa Fluor® and unlabeled,
containing protofibrils or fibrils (10 µL) were applied to a 200-mesh Formvar-coated
copper grid (Ted Pella, Inc.) Samples were allowed to adsorb for 10 min at 25 °C,
followed by removal of excess sample solution. Grids were washed three times by
placing the sample-containing side of the grid down on a droplet of water. Heavy metal
staining was done by incubation of the grid, sample side down, on a droplet of 2% uranyl
acetate (Electron Microscopy Services, Hatfield, PA) for 5-10 min, removal of excess
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Table 2.1 Stoichiometry of protofibrils and monomer peak fractions. Average
fluorophore:protofibril = 0.14 ± 0.03. Average fluorophore:monomer = 0.50 ± 0.08.
Calculated as described in Methods 2.2.3.
PROTOFIBRILS
Prep
1
2
3
4
5
6
7

Fluor., µM
4.1
3.9
3.4
3.7
4.6
3.9
4.3

Ab, µM
37
45
47
26
32
20
18

MONOMERS
Fluor:Ab
0.11
0.09
0.07
0.14
0.14
0.20
0.24

Prep
1
2
3
4
5
6
7
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Fluor., µM
19
22
13
17
20
16
21

Ab, µM
51
58
27
50
39
25
28

Fluor:Ab
0.37
0.38
0.48
0.34
0.51
0.64
0.75

solution, and air drying. Affixed samples were visualized by Dr. David C. Osborn with a
JEOL JEM-2000 FX transmission electron microscope operated at 200 keV.
Visualizing the AF488-Ab42 protofibrils with transmission electron microscopy
allowed me to verify that they had the same length and curvilinear morphology as the
unlabeled Ab42 protofibrils. Figure 2.6 shows the similarities between both labeled and
unlabeled Ab42 protofibrils and fibrils. While the AF488-Ab concentration (38 µM) used
for preparing the TEM grid makes for a crowded image (Panel B), the morphology of the
protofibrils is unmistakable (compare Panels A and B) and was not affected by the
attachment of the fluorophore. Similarly, the label did not affect aggregation, as
monomers were able to aggregate into fibrils. The image shows fibrils formed from
monomers after 53 days at 4 °C, but fibrils formed in other labeled monomer samples in
as little as two weeks at 4 °C.
2.2.5 Dynamic light scattering
Hydrodynamic radius (RH) measurements of Ab protofibrils, and of
microvesicles, were made at room temperature with a DynaPro Titan instrument (Wyatt
Technology, Santa Barbara, CA). Samples (30 µL) were placed directly into a quartz
cuvette and light scattering intensity was collected at a 90° angle using a 10-s acquisition
time. Particle diffusion coefficients were calculated from auto-correlated light intensity
data and converted to RH with the Stokes-Einstein equation. Average RH values were
obtained with Dynamics software (version 6.7.1). Histograms of percent intensity vs. RH
were generated by Dynamics data regularization, and intensity-weighted or massweighted mean RH values were derived from regularized histograms. Figure 2.7
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Figure 2.6 Transmission electron micrographs of unlabeled Ab42 and AF488-Ab42. (A)
Unlabeled protofibrils, 10 µM; (B) AF488-protofibrils, 38 µM; (C) Fibrils formed from
unlabeled monomers, 10 µM; (D) Fibrils formed from AF488-monomers, 37 µM. A and
C scale bars = 100 nm (Paranjape, Terrill, and Gouwens, et al., 2013); B and D scale bars
= 50 nm (Gouwens, et al., 2016).
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demonstrates the similar hydrodynamic radii for both unlabeled Ab and AF488-Ab
protofibrils. The mean RH for unlabeled protofibrils (average of five preps) formed in
aCSF was reported as 21.9±4.0 nm (Paranjape, Terrill, and Gouwens, et al., 2013) and for
AF488-Ab protofibrils formed in aCSF the mean RH = 16 nm, range = 5-50 nm
(Gouwens, et al., 2016). While I have conducted DLS measurements for other
investigations, the measurements of Ab42 were made by Dr. Nichols and we discussed
the data.
DLS was also used to determine microvesicle size. Again, measurements were
made by Dr. Nichols and there were subsequent discussions of the data. Microvesicle
characterization by DLS is discussed in Section 5.1.3 of Chapter 5.
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Figure 2.7 Dynamic light scattering (DLS). Protofibrils were analyzed by DLS
immediately after SEC isolation. Representative regularized histograms of percent
intensity vs. hydrodynamic radius are shown. Left: Histogram for unlabeled protofibrils
prepared in aCSF, mean RH = 23 nm (Paranjape, et al., 2013). Right: Histogram for
AF488-protofibrils in aCSF, mean RH = 16 nm (Gouwens, et al., 2016).
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2.3 Cell Culture
2.3.1 BV-2 microglia culture
BV-2 cells are an immortalized murine microglial cell line derived from primary
murine microglia by stable transfection with the J2 virus, a v-raf/v-myc oncogenecarrying retrovirus (Blasi, et al., 1990). Our BV-2 cells were provided by Dr. Gary
Landreth, Case Western Reserve University, and were maintained in Dulbecco’s
modified Eagle’s medium (DMEM, 4.5 g/L glucose, Hyclone) containing 50 U/mL
penicillin, 50 µg/mL streptomycin, 50 µM b-mercaptoethanol, and 5% heat inactivated
fetal bovine serum (FBS, Hyclone) in 75 cm2 flasks (Corning). BV-2 cells were used for
their ease of culture, to make initial observations comparing them to primary cells, and
for the optimization of microglia-Ab interactions. After thawing, 1.5 mL BV-2 cells (1e6
cells/mL) are added to 5 mL growth medium and centrifuged at 500xg for 7 min. The
supernatant is removed by vacuum aspiration, then the cell pellet is resuspended in 10
mL growth medium and the cell solution is added to a T75 cell culture flask (Corning).
Cells are passaged twice weekly as follows. Growth medium is removed and,
after rinsing with 1 mL sterile PBS, 1 mL 0.25% Trypsin (Sigma) is added to the flask to
dislodge adherent cells from the bottom of the flask. The cells are then incubated for 7
min at 37 °C. 9 mL of growth medium is added to the flask, and from that volume 3 mL
are transferred to a 15-mL conical tube, which is centrifuged at 500xg for 7 min. For the
first passage after thawing, 3 mL are spun down, and for the second passage 1 mL is spun
down. The amounts centrifuged will then alternate between 3 mL and 1 mL in order to
keep the BV-2 concentration at an optimal level.
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2.3.2 Primary microglia isolation and culture
Primary murine microglia were obtained from wild-type (WT) C57BL/6 (Harlan
Laboratories). Care and breeding of the C57BL/6 parent mice were done at the University
of Missouri-St. Louis Animal Facility. Isolation of microglia was conducted as described
in Esen and Kielian (2007) and Paranjape et al. (2012). 3-4-day-old mouse pups were
euthanized with an overdose of inhaled isoflurane (Fisher Scientific). Brains were
isolated and meninges were removed under sterile conditions. Brain tissue was minced
using sharp-edged forceps, resuspended in 0.5% trypsin (Hyclone), and incubated at 37
°C with shaking for 20 min to allow further dissociation of the tissue. Subsequently, the
tissue was resuspended in complete DMEM containing 10% FBS, 4 mM L-glutamine,
100 U/mL penicillin, 0.1 mg/mL streptomycin and 0.25 µg/mL amphotericin-B (Fisher
Scientific), OPI medium supplement (oxaloacetate, pyruvate, insulin, Sigma), and 0.5
ng/mL recombinant mouse granulocyte-macrophage colony-stimulating factor (GM-CSF,
Invitrogen). The cell suspension was further triturated using a pipet and filtered through a
70 µm cell strainer to remove debris. The resulting cell suspension was centrifuged at
200g for 5 min at 25 °C, resuspended in complete medium, and seeded into 150 cm2
flasks (Corning). Cells were cultured at 37 °C in 5% CO2 until confluent (1-2 weeks), and
microglia were selectively harvested from the adherent astrocyte layer by shaking at 250
rpm for 5 h in 5% CO2 at 37 °C followed by collection of the medium. (For isolations
done before 2016, the flask was shaken overnight at 37 °C in 5% CO2.) The flasks were
replenished with fresh medium and then incubated further to obtain additional microglia.
Typically, this procedure was repeated 3-4 times for one flask without removal of the
astrocyte layer. In the bulk of the experimentation, primary microglia were isolated by
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Geeta Paranjape, Shana Terrill-Usery, Sanjib Karki, Ben Colvin, or Nyasha Makoni, and
I handled the care, preparation, plating, treatment, and analysis of the cells for
experiments.
2.4 Microglial AF488-Ab uptake experiments
2.4.1 Ab treatment for ELISA and confocal LSM analysis
For cell uptake studies, WT primary murine microglia, acquired as described
above, were seeded on glass coverslips, in sterile glass-bottom Mat-Tek P35GC-1.5-14-C
culture dishes (Mat-Tek Corp., Ashland, MA) or 96-well cell culture plates at a density of
5 x 105 cells/mL in complete growth medium (volumes of 0.200 mL, 0.200 mL and 0.100
mL, respectively). Prior to cell treatment, growth medium was replaced with assay
medium (growth medium lacking FBS and GM-CSF). Lysosome labeling was done prior
to cell treatment by adding 0.100 mL assay medium containing 0.100 µM LysoTracker®
Red DND-99 (Invitrogen) and incubating for 30 min at 37 °C in 5% CO2. For treatment
times >6 h, LysoTracker® was added to the assay medium 30 min before treatment
ended. Cells were then incubated at 37 °C in 5% CO2 with AF488-labeled Ab (AF488Ab), unlabeled Ab42, aCSF control, or AF488 dye fraction. Times of incubation and
concentrations of AF488-Ab, unlabeled Ab and AF488 dye are noted in figure legends.
Following incubation, the conditioned medium was collected and stored at -20 °C for
subsequent analysis by enzyme-linked immunosorbent assay (ELISA) or immuno-dot
blot. Adherent microglial cells were rinsed 3X with 0.05% Tween 20 in phosphate
buffered saline (PBST) and then fixed with 3.7% formaldehyde for 15 min. Fixed cells
were stored overnight at room temperature in the dark before confocal microscopy
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analysis. Microglia were seeded on glass coverslips by placing a 100-200 µL drop of cell
suspension in the middle of the coverslip, which was in a 30 mm culture dish. A lid was
placed over the culture dish to prevent evaporation during incubation. Microglia were
able to adhere to the coverslip, Medium changes were accomplished by placing a pipet
tip at the edge of the droplet and removing the liquid. Treatment was applied by gently
adding 100 µL to the area of the coverslip occupied by the microglia. After fixing for
immunofluorescence or direct fluorescence, followed by staining of the nuclei, the
coverslip was placed upside-down over a 50-µL droplet of PBS or ProLong Gold
Antifade Mountant (Thermo Fisher Scientific) on a microscope slide.
2.4.2 Ab treatment for fluorescence plate reader and dot blot analysis
Primary WT murine microglia were plated in Nunc F96 Nunclon sterile 96-well
black plates at a density of 5 x 105 cells/mL in complete growth medium (0.1 mL
volume). Times of incubation and concentrations of AF488-Ab, unlabeled Ab are noted
in figure legends. In order to remove Ab from the cell surface membranes, a more
thorough wash protocol was utilized for these studies. Medium was removed from treated
cells and placed in clean wells in the plate. Each cell-containing well was rinsed 3X with
100 µL sterile PBS. An acid wash (100 µL) was performed using a solution of 0.5 M
NaCl and 0.2 M acetic acid for 15 minutes at 4 °C, then cells were rinsed 2X with PBS.
All PBS and acid washes were moved to either clean wells or another plate for both
fluorescence and dot blot analysis.
For intracellular extract preparation, microglia were lysed for 15 min at 25 °C
with 35-50 µL radio immunoprecipitation assay (RIPA) buffer containing 150 mM NaCl,
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20 mM Tris, 1 mM ethylenedaminetetraacetic acid (EDTA), 1% Triton X-100, 1%
deoxycholic acid, 0.1% sodium dodecyl sulfate (SDS), and protease inhibitor cocktail
(Sigma) at a 10X dilution. In some cases, multiple microglia wells were combined to
yield higher concentration lysates. Microglial lysates were stored at -20 °C for further
analysis.
2.4.3 BV-2 microglia cell binding assay
BV-2 microglia were removed from culture flasks with 0.25% trypsin. Cells were
counted using a Cellometer® (Nexcelom Bioscience), pelleted by centrifugation at 500xg
for 7 min, and resuspended at a concentration of 5 x 105 cells/mL. 0.2 mL cells were
seeded in sterile glass-bottom Mat-Tek P35GC-1.5-14-C culture dishes (Mat-Tek Corp.,
Ashland, MA) at a density of 5 x 105 cells/mL in assay medium (growth medium lacking
FBS). Prior to cell treatment, adherent cells were rinsed once with assay medium. Cells
were treated with AF488-Ab or unlabeled Ab42 (concentrations indicated in figure
legends) and then incubated at 4 °C, room temperature, or 37 °C in 5% CO2 for 30 min.
BV-2 cells were rinsed 3X with 0.05% Tween 20 in phosphate buffered saline (PBST)
and then fixed with 3.7% formaldehyde (15 min, room temperature) for confocal
microscopy analysis. BV-2 microglia treated with unlabeled Ab underwent the
immunofluorescence assay described in Section 2.6.
2.5 Fluorescence quantitation for AF488-Ab-treated microglia
To quantitate AF488-Ab internalization, in situ cellular fluorescence
measurements were carried out using a Perkin Elmer Victor 3 multi-mode plate reader.
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Excitation and emission filters were 485 nm and 535 nm, respectively, with a 0.1 second
signal averaging time.
The first experiments I conducted using a black plate and the plate reader
employed BV-2 cells treated with AF488-Ab. While the data (not shown) indicated some
concentration-dependent differences in the fluorescent signal, the signal-to-noise ratio
was small, and there was no way to determine if the fluorescence was from Ab inside the
cells, on the cells, or both. The use of an acid wash, 0.5 % NaCl and 0.2 % acetic acid, to
remove antibodies on cell surfaces was reported in 2007 (Liu, et al., 2007) and I used this
wash for primary cells treated with AF488-Ab. First, a “proof of concept” experiment
was done to assess the ability of a plate assay to measure uptake. Primary microglia were
treated with 5 µM AF488-Ab monomers or protofibrils (3 wells each), 5 µM unlabeled
Ab42 monomers or protofibrils (3 wells each), 1 µM AF488-Ab protofibrils (3 wells)
and aCSF control (3 wells). The plate was incubated for 30 min at 37 °C, 5% CO2. After
transferring the assay medium to clean wells, there were three washes with PBS (100 µL
per well), then the acid wash (100 µL per well), and two more washes with PBS
followed. All washes were transferred to clean wells. Because of this extensive washing
including the acid wash, the fluorescence measured in the cell-containing wells reflects
only internalized AF488-Ab. Figure 2.8 shows the fluorescence intensity readings
measured by plate reader. Negligible fluorescence intensity was measured in the cells
treated with unlabeled Ab42 and the control wells. The lack of fluorescence intensity
difference between AF488-Ab42 monomer and protofibril treated cells is not what I
usually see. Monomer-treated cells are expected to have less fluorescence than
protofibril-treated cells. The AF488-Ab42 was about two weeks post-purification,
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Figure 2.8 Plate reader fluorescence, AF488-Ab. Representative data showing
fluorescence from a microglia treatment experiment. The fluorescence in the cells is what
remains after acid washing. Fluorescence in the acid wash wells represents AF488-Ab
removed from outer cell membrane surfaces. Inset: Fluorescence in cells after washes.
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though, and so had already begun to aggregate. There is a difference between the 1 µM
and 5 µM AF488-Ab42 protofibril-treated wells, so from this I knew this assay was
sensitive enough to measure uptake differences in concentration and could probably be
used in time dependent experiments. It was advantageous to measure uptake this way
since using the 96-well plates allowed for more treatment conditions and replicates
without using more reagents – especially AF488-Ab – and plate reader measurements
were less time-consuming and more objective than quantitating fluorescence images.
2.6 Immuno-detection of Ab and confocal microscopy
2.6.1 Preparation of fixed cells for microscopy
BV-2 and primary murine microglial cells were stimulated, treated and fixed as
described above (Section 2.4.1). Cell samples were then washed 3X with PBST. Cell
nuclei were visualized by incubation for 5 min with 0.2 mL of 0.3 µM 4’,6-diamidino-2phenylindoledihydrochloride (DAPI). After a final wash step, 1-2 mL PBS was applied to
the Mat-Tekä dishes to avoid cellular dehydration. In some cases, ProLong Gold
Antifade (Thermo Fisher Scientific) was applied, the well was covered with a glass
coverslip and the antifade mountant was allowed to set overnight. Microglia treated with
AF488-Ab were imaged directly without further manipulation.
For microglia treated with unlabeled Ab42, fixed cells were incubated for 1 h
with blocking buffer (10% w/v dried milk in PBST). Samples were washed 3X with
PBST after this step and each subsequent step. All incubations were conducted with
gentle shaking at 25 °C. After blocking, samples were incubated for 1 h with the anti-Ab
antibody Ab9 (1:5000 dilution in PBST with 5% w/v dried milk) followed by a 1 h
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incubation with donkey anti-mouse IgG antibody conjugated to Northern Lights (NL)
493 (R&D Systems).
Lysosomal Lamp1 detection was done by immunostaining in a manner similar to
that for unlabeled Ab. After incubating for 1 h in a blocking buffer of PBS containing 1%
bovine serum albumin (BSA) with gentle shaking, the cells were rinsed 3X with PBST.
Next, a 1:500 dilution of anti-Lamp1 primary antibody (Novus Biologicals) into PBS
containing 1% BSA and a 1:100 dilution of anti-mouse IgG-NL637 secondary antibody
(R&D Systems) into PBS containing 1% BSA were each incubated for 1 h with gentle
shaking and rinsed 3X with PBST. After a final wash step, cell nuclei were
counterstained with DAPI and 1 mL PBS was applied to the wells to avoid cellular
dehydration.
2.6.2 Confocal microscopy
The light coming from a specimen in confocal microscopy is controlled by a
pinhole so that its source is limited to a single plane through the specimen. The resulting
image is therefore of a slice through the cell. Any visible fluorescence is from a
fluorophore within that plane of the cell, not above or below. In addition, when multiple
fluorophores are used, channels can be used, as shown in Figure 2.9B, so that only
particular wavelengths are collected during a scan. During the next scan of the same
plane, another set of wavelengths can be collected. This prevents crosstalk resulting from
the emitted light of one fluorophore exciting another fluorophore. If that happened, the
recorded light emission that would be incorrectly attributed to the first fluorophore. For
the work reported herein, the signal from each fluorophore was collected individually.
Both two-dimensional and Z-stack images were obtained with a Zeiss LSM 700
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Figure 2.9 Confocal laser scanning microscopy. TOP: Light beam path. Light emission is
captured point by point, and the light reaching the detector is limited by the pinhole
before it reaches the detector. BOTTOM: Light collection channels. Collecting light in
only one part of the spectrum at a time limits cross-talk. The setting used most often for
the images in my research is the second, where each part of the spectrum is collected
separately. (From Carl Zeiss LSM 700 Operating Manual, September 2011)
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confocal microscope at 40X magnification using ZEN 2009 imaging and analysis
software. Excitation wavelengths used were 405 nm (DAPI), 488 nM (AF488-Ab42 and
anti-mouse IgG-AF488 secondary antibody), 561 nm (LysoTracker® Red, Invitrogen),
and 639 nm (antimouse IgG-NL637 for Lamp1, R&D Systems). For comparison
experiments, all optical and electrical settings were fixed at identical levels for each
image to ensure that fluorescence intensity measurements were not influenced by
different settings.
Confocal fluorescence images were quantitated with ImageJ software (NIH) using
a procedure detailed by Ansari, et al. (2013). Briefly, a region of interest was drawn
around each cell using a polygon drawing tool. Area and integrated density were
measured for each cell using ImageJ. Background fluorescence was measured by
averaging five random areas between cells in the field. The corrected total cell
fluorescence (CTCF) was calculated as follows: [integrated density of total cell area –
(total cell area x mean background fluorescence)].
A second method of quantitation involved selecting the channel for fluorescence
produced by AF488-Ab, changing the color presentation to grayscale, and measuring
integrated fluorescence intensity using ImageJ. Integrated density was divided by the
number of cell nuclei in the field. Excel was employed to compile the data from separate
experiments and calculate error. These two methods were used for experiments in which
the plate reader assay described in Section 2.5 was not used.
2.7 Immuno-dot blot
A nitrocellulose membrane was soaked in water and allowed to dry completely.
Microglial cell lysates (1.7 µL) were spotted onto the membrane and allowed to dry for
42

20 min. Subsequent incubation and washing steps were carried out with gentle shaking
(70 rpm on a rotary platform shaker) at 25 °C. The membrane was placed in a blocking
buffer of phosphate buffered saline (PBS) containing 0.1% Tween-20 and 5% dry milk
and incubated for 1 h, followed by washing 3X for 5 min with PBS containing 0.2%
Tween-20, pH 7.4 (0.2% PBST). Incubation for 1 h in a 1:5000 dilution of mouse antiAb primary antibody Ab9 in PBS containing 1% dry milk and 0.1% Tween-20 was
followed by incubation for 1 h in a 1:1000 dilution of anti-mouse IgG-HRP secondary
antibody in the same buffer. The wash steps detailed above were done after the primary
and secondary antibody incubations. The nitrocellulose membrane was then treated with
ECL western blotting substrate solution (Pierce) and washed for 1 min with accelerated
shaking at 120 rpm. After drying, the membrane was exposed to film for 60 secs in an
autoradiography cassette. The film was developed, fixed, washed in water and dried for
scan analysis. Duplicate dot blot membranes were probed for GAPDH as a control
intracellular protein. The procedure differed only in the primary antibody, using mouse
anti-GAPDH antibody (1:1000 dilution). Densitometry was performed on dot blot film
images using ImageJ software (NIH). Victoria A. Rogers and Nyasha J. Makoni
performed the immuno-dot blot analyses.
2.8 ELISA
Measurements of tumor necrosis factor a (TNFa) were done by enzyme-linked
immunosorbent assay (ELISA). 96-well plates (Nunc, Fisher Scientific) were coated with
100 µL per well of 4 µg/mL monoclonal anti-mouse TNFa capture antibody (R&D
Systems) and incubated overnight at 25 °C. 100 µL of 4 µg/mL monoclonal anti-mouse
TNFa capture antibody (R&D Systems), washed with PBS containing 0.5% Tween-20
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and blocked with PBS containing 1% bovine serum albumin (BSA), 5% sucrose and
0.05% NaN3 followed by a wash step. Successive treatments with washing in between
were done with samples or standards, biotinylated polyclonal anti-mouse TNFa detection
antibody (R&D Systems in 20 mM Tris with 150 mM NaCl and 0.1% BSA, streptavidinhorseradish peroxidase (HRP) conjugate, and equal volumes of HRP substrates 3,3’,5,5’tetramethylbenzidine and hydrogen peroxide. The reaction was stopped by the addition of
1% H2SO4 solution. The optical density of each sample was analyzed at 450 nm with a
reference reading at 630 nm using a SpectraMax 340 absorbance plate reader (Molecular
Devices, Union City, CA). The concentration of TNFa in the experimental samples was
calculated from a mouse TNFa standard curve of 15-2000 pg/mL. When necessary,
samples were diluted to fall within the standard curve.
2.9 Microvesicle generation and isolation from BV-2 and primary microglia
BV-2 microglia seeded into a T-150 flask (Fisher) were cultured to confluence.
The growth medium was then removed, and the cells were rinsed once with sterile PBS, 4
mL per flask. The PBS was removed and 4 mL aCSF was added to the control flask while
4 mL aCSF with 1 mM ATP was added to the treatment flask. Both flasks were incubated
at 37 °C in 5% CO2 for 10 minutes. The aCSF was removed and transferred to a labeled
15-mL conical tube to be centrifuged at 2000xg for 20 mins (Crescitelli, et al., 2013).
Pellets formed in that spin contain apoptotic bodies or even whole cells, but the
microvesicles are soluble and will remain in the supernatant. The supernatant is collected,
distributed into four labeled 1.5 mL microcentrifuge tubes, 1 mL each, and 3.8 µL 2-(6(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)haxanoyl-1-hexadecanoyl-sn-glycero-3phosphocholine (NBD C6-HPC) was added to each tube (final [NBD C6-HPC] = 10
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µM). Tubes were then centrifuged at 12,200xg for 40 mins to pellet the microvesicles
(Crescitelli, et al., 2013). Supernatants were removed and kept for further analysis. One
of the pellets was reconstituted in 200-500 µL aCSF, then the entire volume was
transferred to the second tube to reconstitute another pellet. This process was repeated for
all four tubes to resuspend and concentrate the microvesicles in one volume.
The amount of primary microglial cells available was limited, and so control
experiments in which cells did not receive ATP treatment were not done. Co-cultures of
astrocytes and primary microglia were shaken at 250 rpm for 5 hours to dislodge
microglia. The cells were then counted, centrifuged, resuspended in primary growth
medium and seeded into a T-75 flask. At this point, culture times varied from overnight
to one week. If the cells were cultured for more than 3 days, growth medium was
changed. The primary microglia were treated with 2’(3’)-O-(4-benzoylbenzoyl)adenosine
5’-triphosphate triethylammonium salt (Bz-ATP), which is a better stimulant of the P2X7
receptors on microglia than ATP. The experimental procedure is the same as for BV-2
mciroglia, although the amounts of reagents are smaller since the culture flasks used were
smaller in size. Microglia were rinsed with 2 mL PBS, then 2 mL growth medium with
100 µM BzATP was added. Cells were incubated 10 min at 37 °C in 5% CO2.
Supernatant was collected and centrifuged at 2000xg for 20 min to remove apoptotic
bodies. The supernatant, containing microvesicles, is collected, distributed into two
labeled 1.5 mL microcentrifuge tubes, 1 mL each, and 3.8 µL 2-(6-(7-nitrobenz-2-oxa1,3-diazol-4-yl)amino)haxanoyl-1-hexadecanoyl-sn-glycero-3-phosphocholine (NBD C6HPC) was added to each tube (final [NBD C6-HPC] = 10 µM). Tubes were then
centrifuged at 12,200xg for 40 mins to pellet the microvesicles (Crescitelli, et al., 2013).
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Supernatants were removed and kept for further analysis. One of the pellets was
reconstituted in 200-500 µL aCSF, then the entire volume was transferred to the second
tube to reconstitute another pellet. This process was repeated for both tubes to resuspend
and concentrate the microvesicles in one volume.
2.10 Fluorescence measurements of microvesicles
2-(6-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)hexanoyl-1-hexadecanoyl-snglycero-3-phosphocholine (NBD C6-HPC) (Life Technologies) is a fluorophore
conjugate that inserts into phospholipid membranes. The presence of microvesicles in the
aCSF solution described above (Methods 2.9) was determined using a Cary Eclipse
fluorescence spectrophotometer. 70-100 µL of the microvesicle-NBD C6-HPC solution
was placed in a quartz cuvette. Emission scans of 500-600 nm were obtained with an
excitation wavelength of 485 nm. The resulting curves were integrated from 520-580 nm
to produce relative fluorescence units (RFU).
2.11 Confocal LSM imaging of microvesicles
Annexin V binding was used make the microvesicles visible via confocal
microscopy. Annexin V binds to exposed phosphatidylserine (PS) on the external leaflet
of cell membranes. PS is normally located only on the inner leaflet of the plasma
membrane, but is externalized upon either apoptosis or the membrane blebbing that forms
microvesicles. A conjugate of Annexin V and the Alexa Fluor 488 fluorophore
(Invitrogen) will bind to exposed PS and so it was used to visualize microvesicles. The
microvesicle generation from microglia (Section 2.9) was followed by resuspension of
the pellets in 500 µL Annexin V binding buffer (10 mM HEPES, 140 mM NaCl, and 2.5
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mM CaCl2, pH 7.4). Then 25 µL of -Annexin V conjugate was added, and after gentle
mixing the solution sat at room temperature for 15 min. The solution was then
centrifuged at 12,200xg for 40 min to pellet the microvesicles, the supernatant was
removed, and the pellet was resuspended in 200 µL binding buffer. 50 µL of the
microvesicle solution was placed on a microscope slide and a coverslip was carefully
applied. Images were obtained with a Zeiss LSM 700 confocal microscope, with an
excitation wavelength of 488 nm, using ZEN 2009 imaging and analysis software.
2.12 Preparation of microvesicles for resin-embedded TEM
The protocol used is based on the procedure described in Crescitelli, et al. (2013),
and one of the authors, Dr. Agnes Kittel, was exceptionally helpful by offering
suggestions when I requested details regarding the procedure in the published article.
BV-2 supernatant samples were centrifuged at 12,200xg (or 17,000xg) for 40 mins.
Supernatant was carefully removed and the pellet was rinsed once with PBS. 100 µL of
fixing buffer (4% paraformaldehyde in 10 mM PO4 buffer, pH 7.4) was added to the
pellet without disturbing it, and then incubation occurred at room temperature for one
hour. After carefully removing fixing buffer, 100 µL 1% OsO4 in 10 mM PO4 buffer (10
µL OsO4 in 990 µL buffer) was added to the pellet and allowed to incubate 30 min at
room temperature. (SAFETY PRECAUTIONS for OsO4: gloves, coat, goggles, fume
hood). OsO4 is a secondary fixing agent that incorporates reacts with lipids and provides
contrast for TEM imaging. After incubation, OsO4 was removed and disposed of with
proper safety precautions, and the pellet was washed once with 1 mL diH2O. An ethanol
series was used to dehydrate the pellet (200 µL per tube for each step): 50% ethanol with
2% uranyl acetate 30 min; 70% ethanol for 30 min; 90% ethanol for 30 min; and 100%
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ethanol for 30 min. The 100% ethanol step was repeated twice. The pellet was then
embedded in 0.2 mL Low Viscosity Embedding Media (Spurr’s Kit, Electron
Microscopy Sciences) resin (supplied by David Osborn) and stored at RT overnight. Dr.
Osborn then heated the resin to harden it, cut microtome slices 80 nm thick, and obtained
TEM images.
2.13 BCA Assay
A bicinchoninic acid (BCA) assay was utilized to measure protein concentrations
in microvesicle solutions. In the BCA assay, Cu2+ is reduced to Cu1+ by the presence of
four protein residues (cysteine, cystine, tyrosine, and tryptophan) and the peptide
backbone. First, the copper is chelated and reduced by the proteins in a basic solution.
Then BCA is used to react with the reduced copper, resulting in a purple color. By
measuring absorbance at 562 nm and comparing the samples to a standard curve
generated with bovine serum albumin, protein concentration within the MVs can be
determined. A standard curve was constructed using bovine serum albumin (BSA) diluted
in aCSF, typically in the concentration range of 0 µg/mL to 2000 µg/mL. Microvesicle
samples (10 µl) were added to 100 µl of 50:1 mixture of BCA Reagent A to Reagent B
(Thermo Fisher Scientific) and mixed thoroughly in individual wells of a 96-well plate.
The plate was covered and incubated for 30 min at 37 °C followed by cooling for an
additional 15 min. Absorbance was determined for each well at a wavelength of 562 nm
using a SpectraMax 340 absorbance plate reader (Molecular Devices, Union City, CA).
Mudar Ismail and Natan Zeller conducted the assays and I constructed the graphs.
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CHAPTER 3: Ab INTERACTIONS WITH MICROGLIAL CELL SURFACES
Ab42 is known to interact with microglial surface receptors, leading to uptake and
activation (Section 1.3.1). Previous studies in our lab and had shown that protofibrils can
activate a proinflammatory response in THP-1 macrophages and in microglia, while
monomers and fibrils do not. Being aware of the difference in response to Ab
conformers, we wanted to know if it was related to a difference in surface interaction.
Therefore, my goal was the visualization of Ab42 on outer cell membrane surfaces using
immunofluorescence. I examined the differences in surface binding among monomers,
protofibrils and fibrils of Ab42. I also conducted studies investigating the effects of time,
temperature, and Ab42 concentration on microglial surface interactions. Further, I
investigated the correlation between Ab42 binding to microglia and the subsequent
microglial activation. One distinguishing feature of my work was the use of SEC purified
monomers and protofibrils, as well as fibrils isolated by centrifugation. This differed
from most of the studies in the literature reporting the use of “soluble” Ab, which usually
includes a mix of monomers and multiple aggregated forms.
3.1 Binding of distinct Ab conformers
When BV-2 microglia were incubated with different forms of Ab42 – monomers,
protofibrils and fibrils –immunofluorescence revealed that membrane binding was
occurring only with protofibrils, as shown in Figure 3.1. BV-2 microglial cells were
added at a concentration of 5 x 104 cells/mL in the wells of Mat-Tek dishes (Methods
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Figure 3.1 Binding of distinct species of Ab. BV-2 microglia were incubated for 30 min
at 4 °C with 15µM Ab42 monomers, protofibrils, or fibrils. Control cells were incubated
with assay medium. Ab (green) was visualized via immunofluorescence with anti-Ab
antibody Ab9 (primary) and anti-mouse IgG-NL493 conjugate (secondary). Nuclei were
stained with DAPI (blue). C = control; M = monomer-treated cells; PF = protofibriltreated cells; F = fibril-treated cells. Images were acquired at 40X magnification on a
Zeiss LSM 700 confocal microscope. Scale bar is 16 µm and applies to all four images
(Paranjape, Terrill, and Gouwens, et al., 2013).
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2.4.3). The Mat-Tek dishes have wells with optical glass bottoms to facilitate sample
visualization with an inverted microscope. BV-2 cells were incubated on ice with 15 µM
Ab monomers, protofibrils or fibrils in assay medium, while the control cells were
incubated in assay medium alone. After incubation, cells were fixed and underwent the
confocal assay described in Methods 2.4.3, with Ab9 primary antibody and NL493-IgG
secondary antibody. DAPI chemical staining was used to show cell nuclei. Images were
obtained on the Zeiss LSM 700 located in the Microscope Imaging and Spectroscopy
Technology (MIST) Laboratory in the UMSL Center for Nanoscience.
The reason for holding the temperature at 4 °C was to slow the activity of the
cells and prevent phagocytosis, allowing visualization of cell surface interactions. In
Figure 3.1, monomer-treated cells (M) look like the control cells (C), with no visible
green fluorescence that would indicate the presence of Ab inside or on the cells, while the
cell nuclei (blue) are clearly visible. It is not likely that monomers were taken up and
degraded by the microglia since the low temperature would have interfered with uptake
and metabolic activities. The image of cells incubated with fibrils (F) shows green
fluorescence scattered between the cells, rather than outlining cells, which indicates that
fibrils adhered to the well but not to cell membranes. Only protofibrils (PF) could be seen
on cell surfaces, and they were not readily visible within cells.
One advantage of using the confocal microscope is the ability to acquire a “zstack” in which a number of images are made at successive depths within the field of
view. These slices can then be rendered by Zeiss Efficient Navigation (ZEN) software to
create cross-section images. The PF panel of Figure 3.1 shows this type of imaging. The
thin rectangular section at the top of the image corresponds to a slice through the z-stack
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made at the horizontal green line near the center of the image. Similarly, the rectangular
region to the right corresponds to a slice through the z-stack at the location of the red
vertical line on the image. In all three views of this field, Ab protofibrils are concentrated
on the surface membranes of BV-2 cells. Similar results were seen in replicate
experiments, leading to the conclusion that BV-2 cell membranes interact with
protofibrils of Ab, but not monomers or fibrils.
Binding of Ab to the cell surface membranes of monocytes was assessed
previously by Bamberger, et al. (2003), and they identified a receptor complex consisting
of SR-B receptor CD36, a6b1-integrin, and integrin associated protein CD47 which was
responsible for the interaction. In their binding assays, they used Ab fibrils adhered to
glass slides, applied monocytes to the slides, and counted the number of cells adhering to
the pre-treated slides after a 5-minute incubation. This group was able to show cells
binding to fibrils, but the quantity of Ab used was large enough that the fibrils were
visible to the unaided eye on the slides. It’s possible that the amount of Ab enhanced the
binding and accounts for the difference between our results and theirs. Additionally, fibril
binding may be different for monocytes and microglia.
We did not address the binding of oligomeric Ab to microglia, but this was
investigated by Liu, et al. (2012). They were able to show images of oligomers bound to
microglial surfaces and colocalized with toll-like receptor 2 (TLR2), but the binding was
limited and punctate, while the binding of protofibrils shown here almost completely
covers the cells. The difference could be due to the nature of protofibrils and oligomers
since they are different types of Ab aggregates.
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It is likely that the hydrophobic nature of protofibrils allows them to bind to the
cell membrane indiscriminately even as they trigger receptor-mediated responses in
microglia. Some microglial surface receptors are activated by protofibrils (Section 1.3.1),
resulting in the production of proinflammatory cytokines, and we have confirmed the
secretion of TNFa by BV-2 microglia as a result of protofibril, but not monomer or fibril,
treatment (Paranjape, et al., 2012; Paranjape, Terrill, Gouwens, et al., 2013). Several
microglial receptors are known to interact with Ab, and they can be categorized into three
types: scavenger receptors, G protein-coupled receptors, and toll-like receptors (reviewed
in Yu and Ye, 2014). When distinguishing the Ab species involved in the interactions,
most researchers identify “soluble” or “fibrillar” Ab, without further description.
However, after centrifugation to remove pre-formed fibrils, we carefully separate
monomers from protofibrils using SEC. To my knowledge, there are no published images
that differentiate between these three forms of Ab in binding to microglia.
3.2 Time-dependence of Ab42 interaction with BV-2 cell surfaces
The investigation of membrane interactions between BV-2 microglia and different
conformers of Ab42 revealed that BV-2 cells most readily attract protofibrils, so the next
set of experiments was conducted using this Ab species. A time-dependent measure of
plasma membrane interaction was done by first incubating microglia at 4 °C for 30 min
to allow surface binding while preventing internalization, then varying the times of
incubation at 37 °C. Representative results from these experiments are shown in Figure
3.2. Immunofluorescence revealed the location of Ab mainly on the exterior surfaces of
the BV-2 cells at all time points measured. To rule out the possibility that cell membranes
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30/0

30/30

30/60

30/120

Figure 3.2 Time dependence of surface binding to BV-2 microglia. BV-2 microglia were
plated in Mat-Tek dishes at a density of 5 x 104 cells/mL in cell assay medium. On the
following day, cells were treated with 15 µM Ab42 protofibrils in cell assay medium. All
plates were incubated on ice for 30 min, then incubated for 0 (30/0), 30 (30/30), 60
(30/60), or 120 (30/120) min at 37 °C. Immunofluorescence assay was conducted using
anti-Ab Ab9 primary antibody and anti-mouse IgG-NL493 secondary antibody. Confocal
images were acquired at 40X magnification with a Zeiss LSM confocal microscope.
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were not permeable to the antibodies used in the immunofluorescence assay, an assay
was conducted in which Triton-X 100 was applied to fixed cells before the antibodies
were added. Images acquired after the immunofluorescence assay were nearly identical to
those obtained without the permeabilizing reagent, confirming that the lack of
fluorescence was not due to the inability of antibodies to reach internalized Ab (data not
shown). From the results in Figure 3.2, it was apparent that BV-2 cells were not
internalizing Ab42 even with 2 h of incubation at 37 °C. These results contradict findings
from other groups in which BV-2 cells took up various Ab42 species (Jiang, et al., 2008;
Koenigsknecht and Landreth, 2004; Kopec and Carroll, 1998; Mandrekar, et al., 2009;
Tahara, et al., 2006; Webster, et al., 2001). The Ab42 conformers used in those studies
included monomers, oligomers and fibrils, but were not prepared by SEC. The peptides in
the “soluble” Ab solutions probably contained some oligomers and protofibrils, while
the fibrillar solutions most likely contained oligomers and protofibrils as well.
3.3 Effect of temperature on Ab42 binding to BV-2 cell surfaces
Another possibility for the difference in my results and previous studies is that
treatment for 30 min at 4 °C was negatively affecting the BV-2 microglia such that
uptake was compromised. With that in mind, I also conducted experiments in which the
first 30-minute incubation was conducted at room temperature. The results (not shown)
are similar to the images in Figure 3.2, with Ab42 collecting on the outer cell surfaces of
the microglia. From the results in Figure 3.2, I realized that BV-2 cells are not
internalizing Ab42 even with 2 h of incubation at 37 °C. Therefore, while they are not
proficient at internalization, BV-2 microglia are a good model for cell surface binding in
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Control

4°C

RT

37°C

Figure 3.3 Temperature effect on surface binding to BV-2 microglia. Cells were plated in
Mat-Tek dishes, 5 x 104 cells/mL. On the following day cells were incubated with 15µM
Ab42 protofibrils (green) in assay medium for 30 min at the indicated temperatures. Cells
were fixed, underwent an immunofluorescence protocol with Ab9 primary Ab and IgGNL493 secondary Ab, and were counterstained with DAPI (blue). Images were obtained
at 40X magnification on a Zeiss LSM 700 confocal microscope. (37 °C image from
Paranjape, Terril, and Gouwens, et al., 2013.)
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our culture system. Using immunofluorescence, Ab42 could be visualized on BV-2
microglial surfaces, binding at 4 °C, room temperature (RT), and 37 °C (Figure 3.2). In
Mat-Tek dishes, BV-2 cells were incubated for 30 minutes with 15 µM Ab42 protofibrils,
while control cells were untreated but incubated at room temperature in assay medium
with aCSF for the same amount of time. After cell fixing, the immunofluorescence assay
(Methods 2.6) was conducted and then followed by counterstaining with DAPI, and
images were acquired on a Zeiss LSM 700 confocal microscope. Figure 3.3 shows that
binding occurs on the outer surface of the cell membrane at each temperature measured,
but protofibrils were not taken up by the BV-2 microglia within the 30 minutes of
incubation. If Ab protofibrils were internalized, green fluorescence would be visible
throughout the cells, rather than concentrated on the membrane boundaries. The z-stack
views confirm that, for all three temperatures, protofibrils accumulate at BV-2 cell
surfaces in our system. While the groups cited above (and shown in Table 3.1)
demonstrated uptake at various time points, the species of Ab42 they used varied in size
from monomers to fibrils, and none were SEC-purified protofibrils.
3.4 Effect of Ab42 concentration on binding to BV-2 cell surfaces
We reported concentration-dependent production of TNFa by microglia in 2012
(Paranjape, et al., 2012). Both primary and BV-2 microglia showed increased TNFa
production upon incubation with increasing concentrations of Ab. While the Ab
treatments reported in 2012 were carried out in F-12 medium (131 mM NaCl, 3 mM KCl,
1 mM NaH2PO4, 14 mM NaHCO3, 0.003 mM MgCl2, 0.3 mM CaCl2, 10 mM glucose),
the work reported in 2013 utilized artificial cerebrospinal fluid, (aCSF; 130 mM NaCl, 3
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Table 3.1 Ab internalization in BV-2 microglia and other cell lines
Reference

Ab form

Ab label

[Ab], µM

Cell type

Incubation time

Kopec and
Carroll,
1998

“aged”
(probably
fibrillar)

unlabeled
(fluorescent
microspheres)
or free Ab

5

BV-2

1h

Webster, et
al., 2001

fibrils

fluorescein

10

BV-2

30 min

yes (FACS,
fluorescence
microscopy)

Koenigschnect
and
Landreth,
2004

fibrils
(oligomers
possibly
present)

Cy3

10

BV-2

30 min

yes (confocal
microscopy)

Tahara, et
al., 2006

polydisperse
mixture

none

1

BV-2

24 h

yes (western blot,
ELISA,
immunofluorescence)

Halle, et
al., 2008

fibrils

FITC

10

immortalized
mouse line

4h

yes (confocal
microscopy)

fibrils

HLF488

10

immortalized
mouse line

4h

yes (confocal
microscopy)

10

immortalized
mouse line

1h

yes (confocal
microscopy)

10

immortalized
mouse line

4h

yes (confocal
microscopy)

Uptake (method)
yes (flow
cytometry)

FITC
fibrils
FITC
fibrils

Jiang, et
at., 2008

monomers
and small
oligomers

AF488

0.5

BV-2

0-3 h

yes (flow
cytometry)

monomers
and small
oligomers

AF488

up to 1

BV-2

3h

yes (ELISA of
lysates)

monomers
and small
oligomers

Cy3

0.5

BV-2

15 min

yes (confocal
microscopy)

continued on next page
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Table 3.1 Ab internalization in BV-2 microglia and other cell lines, continued
Reference

Ab form

Ab label

[Ab], µM

Cell type

Mandrekar, et al.,
2009

soluble or
fibrillar

Cy3

0.5

monomers

AF488

monomers

Uptake (method)

BV-2

Incubation time
3h

0.5

BV-2

0-180 min

yes (flow
cytometry and
lysate ELISA)

Cy3

0.5

BV-2

3h

yes (confocal
microscopy)

monomers

Cy3

0.5

BV-2

0-19 min

yes (confocal
microscopy, live
imaging)

ReedGeaghan, et
al., 2009

fibrils (with
oligomers)

none

2.5

BV-2

3-5 min

yes (fluorescence
microscopy)

Fu, H, et al.,
2012

fibril

AF488

0.5

N9 cell line

1h

yes (confocal
microscopy)

fibril

AF488

0.5

N9 cell line

0, 15, 30,
60 min

yes (flow
cytometry)

fibril

AF488

0.05, 0.25,
0.5, 1.0, and
2.5

N9

2 h or 5 d

yes (flow
cytometry)

fibril

AF488

0.5

N9

1h

yes (confocal
microscopy)

Baik, et al.,
2016

fibril

FITC

1

BV-2

24 h

yes (confocal
microscopy)

Paranjape,
Terrill, and
Gouwens, et
al., 2013*

protofibrils

none

15

BV-2

30 min

no (confocal
microscopy)

Gouwens, et
al., 2016*

protofibrils

AF488

5

BV-2

30 min

no (confocal
microscopy)

Abbreviations:
AF488: Alexa Fluor 488
FITC: fluorescein isothiocyanate
HLF488: HiLyte Fluor 488
*results presented herein
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yes (confocal
microscopy and
flow cytometry)

mM KCl, 1 mM NaH2PO4, 15 mM NaHCO3). The same concentration-dependent effect
on TNFa production was seen with BV-2 cells in aCSF, as shown in Figure 3.4
(Paranjape, Terrill, and Gouwens, et al., 2013). BV-2 cells were treated with Ab42 at
various concentrations. ELISAs were conducted on cell medium samples to measure
TNFa, a proinflammatory cytokine produced by microglia when activated. Panel A of
Figure 3.4 shows a concentration-dependent increase in TNFa production for BV-2
microglia. The location of Ab42 on or in BV-2 microglia was assessed by
immunofluorescence and confocal microscopy. Panels B and C of Figure 3.4 show very
little fluorescence on the surfaces of BV-2 cells treated with 1 µM Ab42, while Panel D
shows markedly more intense fluorescence on the BV-2 cell membranes. Taken together,
these images reveal a concentration-dependent pattern of Ab binding to BV-2 cell
membranes. These data are in agreement with the our research (Paranjape, et al., 2012;
Terrill-Usery, et al., 2014) and the findings of other groups (Combs, et al., 2001; Meda, et
al., 1995; Stewart, et al., 2010; Yan, et al., 1996) that microglia produce TNFa upon
stimulation with Ab.
3.5 Correlation of Ab42 binding and BV-2 activation
The surface interaction of Ab42 with BV-2 microglia leads to activation and the
production of cytokines. Not all forms of Ab42 can elicit an inflammatory response as
measured by cytokines, though. Our lab demonstrated this in 2012 (Paranjape, et al.,
2012) and 2013 (Paranjape, Terril, Gouwens, et al., 2013) via ELISA, but there were no
images made at the time. In order to correlate binding with activation, I conducted an
experiment that measured TNFa production as BV-2 cells encountered two different
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Figure 3.4 Ab42 concentration dependence of cytokine secretion by BV-2 microglia.
BV-2 cells were treated with 1 and 15 µM Aβ42 for 30 min at 37 °C. (A) TNFα
ELISA; (B & C) Confocal micrographs of cells incubated with 1 µM Aβ42; (D)
Confocal micrograph of cells incubated with 15 µM Aβ42. Green: Aβ42. Blue: nuclei
(Paranjape, Terrill, Gouwens, et al. (2013)
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Ab42 conformers, and obtained confocal LSM images of BV-2 interactions with the
different forms of Ab42 in a parallel experiment. Experiments were carried out on the
same day, with microglia seeded from one batch of cells and Ab from the same labeled
preparation. The only difference was incubation time, because longer time periods were
needed for the TNFa part of the experiments in order to generate measurable amounts of
the cytokine. The data in Figure 3.5 shows the distinct effects that monomers and
protofibrils have on BV-2 microglia. Panel A reveals that BV-2 microglia secrete more
TNFa in the presence of protofibrils than monomers, especially at 6 h. The images in
Panel B show that the difference in activation is correlated with distinct interaction
differences, i.e., BV-2 cells are more prone to interact with protofibrils than monomers.
The report by our lab in 2013 was the first to distinguish between monomers, protofibrils
and fibrils in the activation of primary murine microglia. To my knowledge, no one has
previously shown both images and ELISA data to distinguish between activation due to
monomers and protofibrils in BV-2 microglia.
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A

Control

Monomer

Protofibril

B

Figure 3.5 Correlation of Ab42 binding and BV-2 cell activation. BV-2 microglia were
treated with AF488-Ab to correlate conformer binding with activation. (A) At 2 and 6 h
time points, TNFa production is greater for protofibril-treated cells than monomertreated cells. (B) Images show that BV-2 cells associate with protofibrils but not
monomers. Green = AF488-Ab fluorescence; blue = nuclei (DAPI) fluorescence.
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CHAPTER 4: SELECTIVE INTERNALIZATION OF Ab BY MICROGLIA
Having demonstrated differential binding of Ab42 species to microglia, and the
resulting activation of the cells, I sought to determine the fate of Ab42 once it was
internalized by microglia. The Alexa Fluor® 488-TFP (AF488-TFP) fluorophore was
used to label Ab42 in solutions containing a mix of monomers and protofibrils. The
mixture was labeled before SEC purification based on a report by Jungbauer and
coworkers (2009) showing that labeling peptides after the formation of oligomers and
fibrils, rather than before, resulted in AF488-Ab that was most similar to unlabeled Ab.
After conjugation of the fluorophore to Ab, AF488-monomers and –protofibrils were
separated by SEC. The labeling process and characterization of labeled Ab42 is described
in the Methods chapter, Section 2.2. It proved advantageous to use fluorophore-labeled
Ab because direct fluorescence provided higher quality images than immunodetection,
required less time to prepare cells for imaging than immunofluorescence assays, and
allowed live cell imaging. My objectives were to compare monomer and protofibril
uptake, assess the time- and concentration-dependence of uptake, determine if uptake has
a limit using mixtures of labeled and unlabeled Ab, and confirm colocalization of Ab
with cellular lysosomes.
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4.1 Comparison of unlabeled and fluorescently-labeled Ab42 monomer, protofibril, and
fibril interactions with BV-2 and primary microglia
Once the AF488-Ab had been characterized (Methods 2.2), I set out to assess and
compare the interactions of both BV-2 and primary murine microglia with the labeled
peptide. I wanted to be sure the binding of AF488-Ab to BV-2 microglia was similar to
cell surface binding observed with unlabeled Ab. Further, I wanted to be sure that the
interactions of primary microglia with AF488-Ab were similar to unlabeled Ab. In both
cases, I found that the fluorophore label was not affecting Ab-cell interactions. Unlabeled
Ab42 was detected via immunofluorescence, and three comparisons are shown in Figure
4.1. The top two panels compare primary microglia treated with 5 µM unlabeled (left)
and labeled (right) monomers for 30 min, with no significant differences between the
images. There is a negligible amount of green fluorescence shown in the images, which
indicates that monomers have not been internalized by the primary microglia. Previous
data shows that BV-2 microglia do not bind or internalize Ab42 monomers (Paranjape,
Terrill, and Gouwens, et al., 2013), and these images confirm that finding for AF488Ab42 monomers. Primary microglia incubated with 5 µM protofibrils for 30 min are
shown in the middle two panels, unlabeled on the left and labeled on the right. The green
fluorescence in the images indicates the location of Ab42. Again, there is virtually no
difference in how primary microglia interact with protofibrils either with or without a
label. The bottom two panels show a comparison of BV-2 microglial surface interactions
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Unlabeled Ab

AF488-Ab

A

B

C

D

E

F

Figure 4.1 The AF488 fluorophore does not affect microglial interactions with Ab.
A & B: primary microglia with unlabeled and labeled monomers, respectively (10 µM,
10 min, 37 °C); C & D: primary microglia with unlabeled and labeled protofibrils,
respectively (5 µM, 10 min, 37 °C); E & F: BV-2 microglia with unlabeled and labeled
protofibrils, respectively (5 µM, 30 min, RT). Green – Ab; blue – cell nuclei
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with both unlabeled (left) and labeled (right) protofibrils upon incubation for 30 min with
5 µM Ab. Most of the Ab42 (green fluorescence) is located on the surfaces of BV-2 cells.
As with the previous comparisons, the two images are similar, indicating that the label
does not affect BV-2 microglial interaction with AF488-Ab.
Additionally, the proinflammatory responses measured by TNFa production show
that primary microglia are activated and produce TNFa when treated with AF488-Ab
protofibrils, but not monomers. Figure 4.2, panel C, shows ELISA results for primary
microglia treated with monomers and protofibrils of labeled Ab. Primary microglia were
activated and produced high quantities of TNFa only when incubated with AF488-Ab
protofibrils. These data agree with our previous results from BV-2 microglia treatments
and primary cell experiments with unlabeled Ab (Paranjape, et al., 2012; Paranjape,
Terrill, Gouwens, et al., 2013).
4.2 Time dependent internalization of AF488-Ab by primary microglia
We had often conducted cell treatments for 30 min or more, yet macropinocytosis
of Ab42 can occur in just a few minutes in microglia (Tables 1.1 and 1.2). To determine
how quickly uptake can occur in our primary microglia, AF488-Ab treatments were
performed as described in Methods 2.4.1. Representative of multiple fields from at least
two experiments, Figure 4.2, Panel A, provides visualization of uptake at four time-points
(green fluorescence is AF488-Ab42, blue is cell nuclei). Monomer internalization is
shown in the top row, and protofibril uptake in the bottom row of Panel A. Compared to
monomers, which show a low level of internalization at all four measured time points,
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Figure 4.2 Internalization of AF488-Ab by primary microglia. Uptake is time dependent
for protofibrils but not monomers. (A) Images of time-dependent uptake of monomers
(top) and protofibrils (bottom). (B) Quantitation of image fluorescence intensity. (C)
TNFa ELISA for the same experiments.
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protofibril internalization is much more robust. Recalling that the stoichiometry of
labeling was about four times higher for monomers than protofibrils, shown in Table 2.1,
it is striking that the fluorescence is so much more intense for protofibrils than
monomers. This is an indication of the speed and extent of Ab42 protofibril
internalization by primary microglia. While the visual evidence is compelling,
quantitation of the images provides more objective evidence of the difference between
monomer and protofibril uptake. By measuring fluorescence intensity per cell in multiple
fields from two different experiments, the graph shown in Figure 4.2, Panel B, was
produced. The data clearly indicate that protofibrils are quickly internalized by primary
microglia, and the uptake of AF488-Ab42 protofibrils increases with time. Also,
monomers are taken up at much lower amounts than protofibrils, even at longer
incubation times.
Monomer uptake (Jiang, et al., 2008; Taneo, et al., 2015) and soluble Ab uptake
(Chu, et al., 1998; Chung, 1999; Hjorth, et al., 2010; Jiang, et al., 2008; Liu, et al., 2010;
Mandrekar, et al., 2009) have been demonstrated by other research groups, and all except
Chu (1999) used labeled Ab. However important differences are present between their
studies and ours. With regard to monomers, Jiang reported a mix of monomers and
soluble Ab, and the Taneo experiments were carried out for 24 h, which is enough time
for monomers to aggregate. In either case, the uptake was most likely of something larger
than monomers. As for the groups reporting internalization of “soluble” Ab, the uptake
was likely not of monomers since soluble species include oligomers and protofibrils.
Another difference involves treatment time points. These experiments involved longer
time points, hours to even days, allowing plenty of time for oligomers and protofibrils to
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form and be taken up. Their data is better compared to our results with SEC-purified
protofibrils in Figure 4.2.
As part of the same internalization experiments, microglial activation was
measured at these time points by looking at cytokine production. The ELISA results
shown in Figure 4.2, Panel C, reveal that the amount of TNFa produced correlated with
AF488-Ab42 protofibril internalization by microglia. At 5 and 10 min of treatment,
measurable TNFa is not present for AF488-Ab42 monomers or protofibrils, but
protofibrils produced a greater amount of TNFa than monomers at 30 min and 6 h.
In another set of experiments, time-dependent uptake of protofibrils and
monomers was quantitated with immuno-dot blot assays of primary microglia cell lysates
using the procedure described in Methods 2.7. Extensive washing of the cells after
incubation with AF488-Ab42, including an acid wash step to remove monomers or
protofibrils bound to the cell surface, allowed quantitation of the intracellular AF488Ab42 at each time point. While there is virtually no uptake of AF488-Ab42 monomers at
any of the time points (Figure 4.3 A & B), the quantity of AF488-Ab42 protofibrils taken
up by primary microglia increases with time. These cell treatments were done in a 96well cell culture plate, and, before lysing the microglia, fluorescence measurements were
made in a plate reader to determine the relative amounts AF488-Ab42 internalized at
each time point (Figure 2.8 and Section 2.5 of Methods). The intracellular fluorescence is
reported as a percentage of the fluorescence in the assay medium removed from the cells
after incubation so that results from different experiments could be combined. The
results, shown in Figure 4.3 Panel C, confirm the findings that protofibrils are more likely

70

Figure 4.3 Primary microglia take up AF488-Ab protofibrils, but not AF488-Ab
monomers, in a time-dependent manner. (A) Immuno-dot blot of cell lysates showing Ab
internalization; representative of three different experiments. (B) Densitometry for
immuno-dot blot in (A) using ImageJ (pixel intensity) for three experiments. (C)
Quantitation of plate reader fluorescence, normalized to fluorescence in cell medium at 0
h for three experiments.
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than monomers to be taken up by primary microglia. Primary murine microglia show a
clear preference for internalizing protofibrils over monomers. Comparison of SECpurified monomers and protofibrils is a novel contribution to the literature regarding
microglial uptake of Ab.
Interestingly, the protofibrils do not appear to be degraded even when microglia
are incubated for 24 h with them. The resistance of Ab to breakdown confirms findings in
the literature. In the late 1990s, Maxfield’s group showed that only a portion of what they
characterized as “microaggregates” (probably oligomers and/or protofibrils) was
degraded by primary murine microglia, most of the Ab remained in the cells (Chung,
1999; Paresce, et al., 1997). Cole and colleagues (1999) reported a 50-60% decrease in
fibrillar Ab in rat microglia after a 24-h treatment. Conducting pulse-chase experiments
in which the treatment medium containing excess Ab was removed, several groups noted
that Ab was retained in primary microglia (Jiang, et al., 2016; Majumdar, et al., 2008;
Majumdar, et al., 2007; Shibuya, et al., 2014). Yang, et al., (2011) were able to show
complete degradation of oligomeric Ab after a 30-minute treatment followed by a 30minute chase, but that is likely due to the fact that they were using oligomers, which have
a different structure than protofibrils. There is a constant supply of Ab being produced in
the brain, so, while a pulse-chase experiment has some value for assessing degradation
rates, it does not accurately reflect physiological conditions.
4.3 Effect of AF488-Ab concentration on primary microglial uptake
This goal for this set of experiments was to determine the effect of AF488-Ab42
concentration on internalization by microglia, comparing monomers to protofibrils.
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Primary microglia were incubated for 10 min (37 °C, 5% CO2) with varying
concentrations of AF488-Ab monomers or protofibrils. As seen in the Figure 4.4
confocal images (Panel A) AF488-Ab monomer uptake is extremely low at all four
concentrations tested, and only slightly visible at 5 and 10 µM concentrations. On the
other hand, AF488-Ab protofibrils are visible in the cells even at 0.5 µM, and
fluorescence appears to increase in intensity as the concentration increases. The
quantitation results in Panel B of Figure 4.4 confirm these observations. The integrated
fluorescence intensity acquired in the AF488 channel for each image was divided by the
number of nuclei in the DAPI channel for each image. Results from three different
experiments were combined. At all four concentrations examined, protofibrils are
internalized at a greater extent than monomers, and internalization of AF488-Ab
protofibrils increases as concentration increases. Once again, it is important to note that
monomers had a higher stoichiometry of labeling, yet the intracellular fluorescence
intensity is markedly stronger for protofibrils. Concentration-dependence of Ab uptake
has been demonstrated in primary murine microglia and in the BV-2 and N9 microglial
cell lines (Fu, et al., 2012; Liu, et al., 2005; Mandrekar, et al., 2009; Yang, et al., 2011),
but as Table 4.1 summarizes, none of these groups compared monomers and protofibrils
purified by SEC as we did. The protofibril uptake findings reported here are novel to the
scientific literature.
4.4 Non-saturable Ab uptake in primary microglia
If there is a limit to the protofibril quantity that can be ingested by primary
microglia, it might be possible to use a mixture of both labeled and unlabeled Ab42 to
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Table 4.1 Primary microglia Ab uptake experiments
Reference

Ab conformation

Ab label

[Ab], µM

Cell
type

Incubation
time

Uptake (method)

Ard, et al.,
1996

“not fibrillar”

35

0.22, 1.1,
4.4, or 25

rat
primary

24 or 48 h

yes
(immunofluorescence;
lysate immunoblot)

Paresce, et
al., 1996

“microaggregates”
<400 nm length

Cy3

0.22

mouse
primary

10 min

yes (fluorescence
microscopy, not
confocal)

Cy3

up to 11

mouse
primary

15 min

yes (fluorescence
microscopy, not
confocal)

unlabeled

4

mouse
primary

30 min

yes (fluorescence
microscopy, not
confocal

Cy3

1

mouse
primary

15 min,
followed by
3 h to 6 d
chase times

yes (confocal LSM)

Cy3

2

mouse
primary

1 h,
followed by
1 h or 2 d
chase

yes (confocal LSM)

125

0.2

mouse
primary

1 h,
followed by
up to 75
min chase

yes (cell associated
radioactivity)

unlabeled

2

mouse
primary

1 h,
followed by
6 and 24 h
chase

yes
(immunofluorescence)

fibrils

125

0.2

mouse
primary

1 h, various
chase times

yes (cell associated
radioactivity)

fibrils

Cy3

0.2

mouse
primary

1 h, various
chase times

yes (confocal image
quantitation)

soluble

125

1

mouse
primary

2 h, various
chase times

yes (cell associated
radioactivity)

soluble

Cy3 and
unlabeled

1 + up to
100
unlabeled

mouse
primary

15 min

yes (confocal image
quantitation)

soluble

Cy3

0.5

mouse
primary

1.5 h, 1 h
chase

yes (confocal
microscopy)

Paresce et
al., 1997

“microaggregates”

S-Met

I

Chung, et
al., 1999

I

I

continued on next page
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Table 4.1 Primary microglia Ab uptake experiments, continued
Reference

Ab conformation

Ab label

[Ab], µM

Cell
type

Incubation
time

Uptake (method)

Cole, et al.,
1999

fibrils

none

0.2

rat
primary

24 h

yes
(immunofluorescence)

Webster, et
al., 2000

“minimally
aggregated”

14

0-50

rat
primary

2 h and 6 h

yes (cell-associated
radioactivity)

“minimally
aggregated”

fluorescein

5, 50

rat
primary

2 h and 6 h

yes
(immunofluorescence)

fibrils/protofibrils

biotin

0.055,
0.55, 5.5

mouse
primary

1h

yes, (quantitation of
confocal microscopy,
AF488)

fibrils/protofibrils

biotin

0.55

mouse
primary

5, 30, 60,
120 min

yes, (quantitation of
confocal microscopy,
AF488)

fibrils/protofibrils

biotin

0.55

mouse
primary

5, 30 min;
1, 2 h

yes, (confocal
microscopy, Cy3streptavidin)

fibrils

FITC

0.3

mouse
primary

15, 30, 60
min

yes (fluorometry of
lysates)

fibrils

none

0.3

mouse
primary

1h

yes (western blot of
lysates)

fibrils

Cy3

0.05

mouse
primary

1h

yes (confocal
microscopy)

Floden and
Combs,
2006

fibrils

FITC

0.5

primary
mouse,
neonatal
and aged

6h

yes (fluorometry)

Tahara, et
al., 2006

oligomers

none

0.25

mouse
primary

24 h

yes
(immunofluorescence
microscopy)

Majumdar,
et al., 2007

fibrils

Cy3

1

mouse
primary

60 min,
then 72 h
chase

yes (fluorescence
image quantitation)

Mandrekar,
et al., 2009

soluble
(monomers with
some small
oligomers) or
fibrillar

Cy3

0.5

mouse
primary

3h

yes (confocal
microscopy and flow
cytometry)

Liu Y, et al.,
2005

Townsend,
et al., 2005

C

continued on next page
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Table 4.1 Primary microglia Ab uptake experiments, continued
Reference

Ab conformation

Ab label

[Ab], µM

Cell
type

Incubation
time

Uptake (method)

Liu Z, et al.,
2010

soluble

HLF555

2

primary
murine

2h

yes (confocal
microscopy)

Majumdar,
et al., 2011

fibril

Cy3

0.25

primary
murine

1 h, chase
times vary

yes (confocal
microscopy)

Yang, et al.,
2011

oligomer

none

1

primary
murine

5 and 30
min; 1 and
4h

yes (confocal
microscopy)

oligomer

none

0.5, 1.0,
2.5, 5.0

primary
murine

30 min

yes (fluorescence
intensity quantitation)

oligomer

FAM

1

primary
murine

15 min

yes (confocal
microscopy)

fibril

AF488

0.5

primary
murine

1h

yes (confocal
microscopy)

fibril

AF488

0.5

primary
murine

0, 15, 30,
60 min

yes (flow cytometry)

fibril

AF488

0.5

primary
murine

1h

yes (confocal
microscopy)

soluble

AF555

0.4

primary
murine

18 h

yes (flow cytometry)

soluble

AF555

0.2

primary
murine

7 min, 10
min chase

yes (confocal
microscopy)

monomer

none

10

primary
murine

24 h

yes (confocal
microscopy)

oligomer

none

10

primary
murine

24 h

yes (confocal
microscopy)

fibril

none

10

primary
murine

24 h

yes (confocal
microscopy)

Baik, et al.,
2016

fibril (PF)

FITC

1

primary
murine

24 h

yes (confocal
microscopy)

Gouwens, et
al., 2016*

monomers

AF488

0.5 – 10

primary
murine

0-24 h

no (confocal
microscopy;
immunodot-blot; plate
reader

protofibrils

AF488

AF488

primary
murine

0-24 h

yes (confocal
microscopy;
immunodot-blot; plate
reader)

Fu, H, et al.,
2012

Lee, CY, et
al., 2012

Taneo, et
al., 2015

Abbreviations: AF488: Alexa Fluor 488; AF555: Alexa Fluor 555; Cy3: Cyanine 3; FAM:
carboxyfluoroscein; FITC: fluorescein isothiocyanate; HLF488: HiLyte Fluor 488

*work presented herein
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Figure 4.4 Concentration-dependent internalization of AF488-Ab by primary microglia.
(A) Images of monomer-treated (top) and protofibril-treated (bottom) cells.
Concentrations indicated above columns. Green – AF488-Ab, blue – nuclei. (B)
Quantitation of fluorescence intensity for AF488-Ab. Fluorescence intensity for the fields
imaged in panel A and two other experiments. ImageJ was used to measure integrated
intensity, which was then divided by the number of nuclei in the field.
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visualize such a limit. Uptake that is receptor-mediated or regulated by a transport
mechanism could prevent the internalization of ever-greater amounts of Ab42. By
maintaining a constant AF488-Ab42 concentration while increasing the amount of
unlabeled Ab42, a decrease in fluorescence would indicate that cells were saturated with
Ab and could not internalize any more. If the fluorescence intensity is not diminished by
increasing the ratio of unlabeled Ab, then the uptake mechanism cannot be saturated (up
to the total amount of labeled + unlabeled Ab in the experiment). To probe the limits of
uptake by primary microglia, unlabeled and AF488-Ab42 were mixed in various ratios
before application to and incubation of microglia. As seen in Figure 4.5, Panel A, the first
set of experiments did not indicate a saturation of uptake even at 20 µM total Ab42. All
three images show similar green fluorescence intensity, indicating AF488-Ab
internalization was not saturable. Different AF488-Ab:unlabeled Ab ratios were used in
another set of experiments, and the image fluorescence intensity quantitation is shown in
Panel B of Figure 4.5. Again, there is no significant difference in measured fluorescence
intensity, even when there is three times as much unlabeled Ab42 mixed with AF488Ab42. These results confirm the findings of Mandrekar et al. (2009) that Ab uptake is not
receptor-mediated, and in addition show that there is no limit to internalization up to 20
µM Ab42. These images show internalized Ab, only the fluorescence on the boundaries
of the cells could be considered as surface-attached Ab. We have shown that the amount
of internalized Ab increases at 6 and 24 h, an increase that would not be present if the
protofibrils were rapidly cycling into and out of the cells. Additionally, it is not likely that
the membranes of the cell could support a rapid turnover leading to equilibrium. Other
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Figure 4.5 Competition/saturation images and quantitation. (A) Representative images of
primary microglia treated with the indicated concentrations of labeled and unlabeled Ab.
(B) Quantitation of fluorescence intensity in images of primary microglia treated with the
indicated concentrations of labeled and unlabeled Ab. ImageJ was used to measure
integrated intensity for each field, which was divided by the number of nuclei in the field.
(n = 2 experiments)
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groups have conducted pulse-chase experiments in which the Ab-containing medium was
removed and the amount of internalized Ab was then measured at different time points.
but their purpose was to measure degradation, not uptake saturation (Chung, 1999; Lee,
et al., 2012; Majumdar, et al., 2011; Majumdar, et al., 2007; Paresce, et al., 1997). While
these groups did show some degradation, it was limited. Even if degradation occurred in
the experiments reported here, it would not be enough to affect the outcome because the
rate of degradation would not be enough to offset uptake, and the rate would be the same
for all of the ratios. Two early studies, involving “microaggregates” or fibrillar Ab
seemed to indicate saturation of uptake, as both groups found that intracellular
fluorescence increased with increasing concentration, but leveled off after 10-11 µM Ab
(Kopec and Carroll, 1998; Paresce, et al., 1996). These two groups did not use ratios as
we did. Other studies used the approach of keeping the amount of labeled Ab constant
while mixing in increasing concentrations of unlabeled peptide, and those groups did
report saturation of uptake (Chung, 1999; Mandrekar, et al., 2009).
4.5 Colocalization analysis of AF488-Ab with lysosomes
The question of whether or not Ab is degraded by microglia is not settled. Two
reports indicated that oligomers are degraded in microglia (Shibuya, et al., 2014; Yang, et
al., 2011) but oligomers do not have the same b-sheet structure as protofibrils or fibrils,
so it is perhaps not surprising that they are degraded. Several studies showed slow and/or
limited breakdown of internalized fibrils (Chung, et al., 1999 ; Majumdar, et al., 2011;
Majumdar, et al., 2008; Majumdar, et al., 2007; Paresce, et al., 1997). Monomers and
soluble species were also shown to be slowly or incompletely degraded (Ard, et al., 1996;
Griciuc, et al., 2013; Jiang, et al., 2008). In these studies, there was no SEC purification
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of protofibrils, so it is possible that both the fibril and soluble solutions used contained
some protofibrillar Ab. Further, the degradation was incomplete when it occurred at all,
so more investigation is warrented. In cells, the break down unwanted material occurs in
the lysosomes, acidic “digestive” organelles. If Ab is being degraded, it would first have
to be trafficked to lysosomes. Many studies have shown Ab colocalized with lysosomes,
and they are summarized in Table 4.1. Various Ab conformers were used for cell
treatments in those experiments, but no one had reported using SEC-purified protofibrils.
In an effort to show colocalization of protofibrils with lysosomes in our primary
microglial system, I had tried using LysoTracker® Red DND-99 (Invitrogen) for labeling
lysosomes prior to cell treatment, but did not have good enough results to definitively
conclude colocalization or lack thereof. Lysosomal associated membrane protein
(LAMP1) is a transmembrane protein that is found on lysosomes in many tissues. To
visualize colocalization of Ab42 and lysosomes, I used immunofluorescence to label the
LAMP1 protein. The primary antibody was anti-LAMP1 (Novus Biological) and the
secondary antibody was anti-mouse IgG-NL637 (R & D Systems). Primary microglia
were treated with AF488-Ab protofibrils, fixed, immunostained, counterstained with
DAPI, and then imaged on a Zeiss LSM 700. The images in Figure 4.6 represent several
experiments. Yellow arrows in the images indicate areas of colocalization (yellow) of
AF488-Ab (green) with lysosomes (red). White arrows in the images show either AF488Ab (green) that is intracellular but not in lysosomes, or empty lysosomes (red). While
other groups have shown Ab-lysosome colocalization in BV-2 and primary microglia,
and some concluded that Ab is degraded in lysosomes, my results indicated that
trafficking to lysosomes is not necessarily the fate of AF488-Ab protofibrils. This is
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Table 4.2 Lysosome colocalization experiments.
Reference

Ab form

Ab label

[Ab], µM

Cell type

Incubation
time

Colocalization
method

Ard, et
al., 1996

“not
fibrillar”

35

0.22, 1.1, 4.4,
or 25

rat primary

24 or 48 h

immunogold, EM

Paresce,
et al.,
1996

“microaggregates”
<400 nm
length

Cy3

0.22

mouse
primary

10 min

FITC-a2M

Paresce et
al., 1997

“microaggregates”

Cy3

2

mouse
primary

1 h,
1 h or 2 d
chase

FITC-dextran

Chung, et
al., 1999

soluble

Cy3

0.5

mouse
primary

1.5 h, 1 h
chase

FITC-a2M

Webster,
et al.,
2000

“minimally
aggregated”

fluorescein

5, 50

rat primary

2 h and 6 h

cathepsin D

Liu Y, et
al., 2005

fibrils/protof
ibrils

biotin

0.55

mouse
primary

5, 30 min;
1, 2 h

Lamp2

Bolmont,
et al.,
2008

plaques

none

endogenous

APP
transgenic
mouse, in
vivo

Halle, et
al., 2008

fibrils

FITC

10

immortalized mouse
line

4h

Lamp1

fibrils

HL488

10

immortalized mouse
line

4h

LysoTracker Red

10

immortalized mouse
line

1h, 4 h

1 h: cathepsin B
4 h: Lamp1 (no
colocalization)

S-Met

Lamp1

FITC
fibrils

Jiang, et
at., 2008

monomers
and small
oligomers

Cy3

0.5

BV-2

15 min

LysoTracker Green

Mandrekar, et al.,
2009

monomers

Cy3

0.5

BV-2

3h

Lamp1, Lamp2, Rab5

monomers

Cy3

0.5

BV-2

0-19 min

LysoTracker Green
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Table 4.2 Lysosome colocalization experiments, continued.
Reference

Ab form

Ab label

[Ab], µM

Cell type

Incubation
time

Hjorth, et
al., 2010

soluble

HL488

0.25

human
CHME3
line

4h

Lamp2

Liu Z, et
al., 2010

protofibril

HL555

0.4

in vivo,
mouse

up to 4 d

Lamp1

Majumdar, et al.,
2011

fibril

Cy3

0.25

primary
murine

1 h, chase
times vary

Lamp1

Yang, et
al., 2011

oligomer

FAM

1

primary
murine

15 min

DQ-BSA lysosome
label

Fu, H, et
al., 2012

fibril

AF488

66 (0.6 µg
total)

mouse in
vivo

2 h or 5 d

Lamp1

fibril

AF488

0.5

N9

1h

LysoTracker

fibril

AF488

0.5

primary
murine

1h

LysoTracker

Lee, CY, et
al., 2012

soluble

AF555

0.2

primary
murine

7 min, 10
min chase

fluorescent
microspheres

Taneo, et
al., 2015

monomer

none

10

primary
murine

24 h

Lamp1 (not
colocalized)

oligomer

none

10

primary
murine

24 h

Lamp 1 (not
colocalized)

fibril

none

10

primary
murine

24 h

Lamp1 (not
colocalized)

fibril (PF)

FITC

1

BV-2

24 h

LysoTracker

fibril (PF)

FITC

1

primary
murine

24 h

LysoTracker

protofibril

AF488

5

primary
murine

30 min

Lamp1 (partial
colocalization)

Baik, et al.,
2016

Gouwens,
et al., 2016

Colocalization
method

Abbreviations: AF488: Alexa Fluor 488; AF555: Alexa Fluor 555; Cy3: Cyanine 3; FAM:
carboxyfluoroscein; FITC: fluorescein isothiocyanate; HLF488: HiLyte Fluor 488; HL555:
HiLyte Fluor 555; 35S-Met: 35S-methionine radioisotope

*work presented herein
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evident in the increase of Ab protofibril load over a 24-h incubation (Figure 4.3) and in
the confocal images of Figure 4.6 which show a significant amount of AF488-Ab
distributed throughout the cytosol. The stability of intracellular SEC-purified protofibrils
in microglia is a novel finding that was reported in Brain Research in 2016 (Gouwens, et
al., 2016).
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Figure 4.6 Lysosome colocalization. Three fields (top, middle and bottom rows) of
primary cells treated with AF488-Ab show that much of the AF488-Ab remains outside
of microglial cells. Yellow arrows indicate lysosome (red, Lamp1) and AF488-Ab
(green) colocalization. White arrows show lysosomes that have no AF488-Ab within
them. Nuclei are stained with DAPI (blue).

85

CHAPTER 5: MICROVESICLES
Having demonstrated that microglia internalize Ab protofibrils without
bnecessarily degrading them, we began to wonder if the protofibrils are released from
microglial cells. If there is a release of Ab, that could partly explain why plaques form in
the AD brain. Structures called microvesicles (Section 1.4) are one way microglia could
disperse Ab. Microvesicles (described in Section 1.4) are released by glial cells when
P2X7 receptors are stimulated by ATP (Bianco, et al., 2005). In their work, Bianco and
colleagues used the N9 murine microglial cell line as well as primary mixed cultures
(containing astrocytes and microglia) from embryonic rat pups to demonstrate the release
of microvesicles from microglial cells. Rat primary microglia (Joshi, et al., 2014), and
human THP-1 monocytes and HEK cells (MacKenzie, et al., 2001) have also been used
in experiments to produce microvesicles. Further, P2X7 receptors of microglia have been
shown to mediate the inflammatory responses in rat hippocampus (McLarnon, et al.,
2006). My goals were to generate and characterize microvesicles from both BV-2 and
primary murine microglia.
5.1 Microvesicles from BV-2 microglia
Due to their small size, capturing a substantial amount of microvesicles requires
treatment of many cells in an experiment. BV-2 microglia are relatively easy to culture in
the amounts needed for microvesicle generation, so I started my experiments with them.
Using T-150 flasks (Corning), which have a 150 cm2 growing surface, the BV-2 cells
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were cultured to confluence. The experiments required two such flasks, a control flask
that was incubated with 4 mL artificial cerebrospinal fluid (aCSF) and a second flask that
was incubated with 1 mM ATP in 4 mL aCSF to stimulate the production of
microvesicles (Methods 2.9). To confirm that microvesicles were produced, we employed
a variety of techniques: fluorescently labeled Annexin V, BCA protein measurements,
dynamic light scattering (DLS) measurements, transmission electron microscopy (TEM),
and NBD C6-HPC fluorescence.
5.1.1. A488-Annexin V visualization of BV-2 microvesicles
Annexin V is an anticoagulant protein that also has a high affinity for
phosphatidylserine (PS). Normally PS is found on inner leaflets of the cell membrane,
but, in apoptotic cells and microvesicles, PS is externalized (Hugel, et al., 2005). We used
Annexin V conjugated to Alexa Fluor® 488 (AF488-AV) to visualize microvesicles
generated in the experiments (Figure 5.1). After the cells were treated, the medium was
subjected to centrifugation at 2000g for 20 minutes to remove apoptotic cells and cell
debris from the medium. Soluble microvesicles are in the supernatant, to which AF488AV was added. After incubation at room temperature, the solution was then centrifuged
at 12,200g for 40 minutes to pellet the microvesicles. The pellet was washed and
resuspended, and microvesicles were mounted on slides and imaged using a Zeiss LSM
700. As seen in Figure 5.1 A & B, the microvesicles are produced by both control (A)
and ATP-treated (B) cells and are in the expected 100 – 1000 nm size range.
Microvesicle production from the control cells (treated with aCSF only) is not necessarily
surprising since microvesicles are routinely found in blood and spinal fluid (Budnik, et
al., 2016), indicating constitutive generation by cells in the body. Panel C of Figure 5.1 is
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a zoomed in view of an area near the center of Panel B which includes a 5 µm scale bar
that confirms the size of the microvesicles. The images here are consistent with
MacKenzie, et al. (2001), who showed a series of HEK cell images taken at 5 s intervals
in which microvesicles are visualized with FITC-conjugated Annexin V bound to
externalized PS. They imaged whole cells, and a halo of microvesicles is visible in the
same size range as our microvesicles. Wilson, et al. (2004) demonstrated external PS
(calling it “PS flip”) in human umbilical vein epithelial cells and murine macrophages.
Their images were not of microvesicles, rather, they showed FITC-Annexin V binding to
the surfaces of macrophages after treatment with ATP, demonstrating PS externalization.
This is the same PS externalization that occurs with microvesicle release. Bianco, et al.
(2005) also show FITC-Annexin V in close association with ATP-stimulated N9
microglia, with a few blebs on the cell surface and structures that have the size and
morphology of microvesicles. The researchers showed images of microvesicles in a
subsequent publication, appearing as dots of fluorescence (Bianco, et al., 2009). One of
the methods of microvesicle visualization used by Verderio, et al. (2012) was FITCAnnexin V. Their image, similar to Bianco’s images, does not show the circular
fluorescence seen in Figure 5C, which is indicative of hollow spheres. The images in
Figure 5 indicate that our protocol for generating microvesicles from ATP-treated BV-2
microglia and separating them from apoptotic bodies via centrifugation is successful.
5.1.2. Bicinchoninic acid protein assay of BV-2 microvesicles
IL-1b has been found in microvesicles generated from human THP-1 monocytes
(MacKenzie, et al., 2001) and dendritic cells (Pizzirani, et al., 2007), as well as murine
microglia (Bianco, et al., 2005) treated with ATP. Therefore, we expected to find protein
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A

B

C

Figure 5.1 AF488-Annexin V visualization of microvesicles from BV-2 cells.
Microvesicles were generated from BV-2 microglia with or without ATP treatment. After
generation from BV-2 microglia, microvesicles were incubated with AF488-Annexin V
and imaged via confocal microscopy. (A) Control: microvesicles generated from
microglia incubated in aCSF without ATP; 40X magnification. (B) Microvesicles
generated from BV-2 microglia treated with 1 mM ATP. 40X magnification; vertical red
scale bar = 20 µm; horizontal red scale bar = 5 µm. C. Zoomed in view of area near
horizontal red scale bar in (B)
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in the BV-2 microvesicles. Bicinchoninic acid (BCA) protein assays were employed to
provide measurements of overall microvesicle protein content. By measuring absorbance
at 562 nm and comparing the samples to a standard curve generated with bovine serum
albumin, protein concentration within the microvesicles can be determined. While both
control and ATP-treated cells produced microvesicles, the microvesicles from treated
cells had much more total protein (Figure 5.2), with virtually no protein in the
microvesicles from control cells. The combined data from four preps showed a protein
concentration of ~150 µg/mL protein in ATP-treated cells compared to virtually none in
the control cells. It is likely that the contents of our microvesicles derived from ATPstimulated BV-2 microglia contain IL-1b, as was found by the MacKenzie, Pizzirani, and
Bianco studies mentioned above. Regarding the control cells, constitutive microvesicle
production is not unusual, and the lack of protein is likely a consequence of there being
no ATP in the aCSF to activate IL-1b production and release.
5.1.3. Dynamic light scattering characterization of BV-2 microvesicles
Particles in solution will move randomly as they collide with molecules of the
solution, and smaller particles will move faster than relatively larger ones. Light passing
into a solution containing microvesicles, for instance, will be scattered upon encountering
a sphere crossing its path. Scattered light then encounters other particles, causing wave
interference that is either constructive or destructive. As the particles diffuse through the
solution, the scattering intensity changes, as does the correlation between the intensities
and interferences. The intensity measurements are fitted to an autocorrelation curve, and
from the exponential decay a diffusion coefficient can be calculated, which is then used
to calculate hydrodynamic radii of microvesicles. We used these principles of dynamic
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Figure 5.2 BCA assays. There is greater protein production in microvesicles generated
from ATP-treated cells than control cells in aCSF. Average of four microvesicle
preparations from BV-2 microglia. (BCA assays conducted by Mudar Ismail and Nathan
Zeller; figure from Dr. Michael Nichols)
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light scattering (DLS) to characterize microvesicle size (Methods 2.2.5). Histograms of
percent intensity vs. hydrodynamic radius (RH) were generated by Dynamics software
(Wyatt Technologies) data regularization, and intensity-weighted mean RH values were
derived from regularized histograms. What we found, shown in the representative
histograms in Figure 5.3, is that the microvesicles we isolated from BV-2 microglia are
approximately 100-1000 nm in size, with an average RH = 129 nm for the ATP-treated
BV-2 microvesicles in 5.3A, and an average RH = 207 nm for the microvesicles in 5.3B,
which were also from ATP-treated BV-2 cells. Microvesicles generated from control
cells in the same experiments had average RH = 136 and 208 nm, respectively. The
defined microvesicle size range is 100-1000 nm, described by Budnik, et al. (2016), and
these representative DLS data for all of the microvesicle preps show that our
microvesicles were within that range
5.1.4. Transmission electron microscopy of resin-embedded BV-2 microvesicles
Microvesicles from BV-2 cells were embedded in resin (Methods 2.11) for
imaging via TEM. Dr. Agnes Kittel’s gracious help was vital to this endeavor. After
reading a paper that featured TEM images of microvesicles (Crescitelli, et al., 2013), I
emailed the corresponding authors and they identified Dr. Kittel as the TEM technician
responsible for the images. Our correspondence led to the method used for obtaining the
images of BV-2 microvesicles in Figure 5.4. The intricate process involved pelleting the
microvesicles, fixing with formaldehyde, treatment with osmium tetroxide, multi-step
alcohol dehydration using uranyl acetate stain in the first step, and resin polymerization.
David Osborn acquired the images shown in Figure 5.4 after slicing the resin-embedded
sample with a microtome. The top panel shows BV-2 microvesicles from control
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5.3 Dynamic light scattering analysis of microvesicles. Microvesicles were generated
from BV-2 microglia. Results from two different experiments are shown. (Figure created
by Dr. M.R. Nichols.)
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Figure 5.4 TEM of resin-embedded BV-2 microvesicles
Top: control BV-2 MVs (no ATP). Bottom: ATP-treated BV-2MVs. Both sets of
microvesicles are within the size range expected. (Resin embedding done by myself and
Mudar Ismail; image by Dr. David Osborn.)
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microglia, and the bottom panel shows BV-2 microvesicles from the ATP-treated
microglia. The microvesicles are similar in size and appearance, despite the presence or
absence of ATP during the experiment. Bianco (2009) and Verderio (2012) presented
TEM of vesicles isolated by differential centrifugation, which they refer to as P2 (1200g),
P3 (10,000g), and P4 (110,000g). The microvesicles from our experiments (Figure 5.4)
correspond to their P3 pellet, and look much like the structures in their images. That is
expected, considering the similarities in our isolation protocols; their 1200g and 10,000g
centrifugations correspond to our 2000g and 12,200g centrifugations. The lower speed
should pellet whole cells, debris, and apoptotic bodies, and the higher speed produces a
pellet of microvesicles. In the Crescitelli, et al. (2013) study, three cell types were used:
human mast cells, human erythroleukemia cells, and BV-2 murine microglia. They were
able to visualize microvesicles from all three, and our BV-2 microvesicles resemble them
in size and appearance. These images provide compelling evidence for our ability to
generate microvesicles from BV-2 microglia.
5.1.5 Tracking microvesicles with NBD C6-HPC fluorescence
The miniscule pellets presented a challenge when isolating microvesicles. To
better track microvesicles, and reassure ourselves that they were indeed present, we took
advantage of the NBD fluorophore conjugated to phosphatidylcholine (PC). The NBD
C6-HPC (Setareh Biotech; Figure 5.5) molecule inserts into lipid bilayers, and its
emission at 536 nm (excitation: 436 nm) can be used to identify membranes. The use of
NBD C6-HPC to visualize microvesicles from healthy rat CSF and to quantify
microvesicles from rat microglial cell culture was reported by Verderio, et al. (2012).
CSF microvesicles isolated from healthy rats were visualized by adding NBD C6-HPC to
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pellet fractions, placing drops onto a slide, and imaging the microvesicles with a
fluorescence microscope. In their work, microglia were pretreated with NBD C6-HPC
before the experiment to label cell membranes, then, after collecting the microvesicles,
the researchers quantified NBD C6-HPC fluorescence intensity to make a comparison of
microvesicle amounts produced by known stimulants of microglial activation and
microvesicle production, such as ATP or LPS. Bianco, et al. (2009) also used NBD C6HPC to label cell membrane lipids and visualize both real-time microvesicle release from
BzATP-treated human glioma cells and microvesicles isolated from cell the culture
medium of BzATP-treated astrocytes.
In our experiments, supernatants from microglia treated with ATP or BzATP were
processed as described in Methods (2.9 and 2.10). NBD C6-HPC is added to the
supernatant collected from the 2000g spin of the cell treatment medium, which pellets
cell debris and apoptotic bodies. The supernatant with fluorophore is then incubated at
room temperature for 10-15 min, after which the microvesicles are pelleted via
centrifugation at 12,200-15,000g and washed with aCSF two to five times to remove
excess fluorophore. A fluorimeter is used to measure fluorescence of the washes and
resuspended pellets. Fluorescence emission is recorded from 500-600 nm, and integrated
from 505-550 nm to produce the values that are graphed. Since most of the
unincorporated fluorophore is removed during the washes, greater fluorescence intensity
in the resuspended pellet compared to the last wash indicates the presence of
microvesicles. Figure 5.5 shows representative data from an experiment in which BV-2
and primary microglia were treated with ATP to stimulate microvesicle production. The
bottom panel shows a comparison among two washes and the resuspended microvesicle
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Figure 5.5 NBD C6-HPC fluorescence indicates the presence of microvesicles.
Top: NBD PC conjugate. Bottom: representative fluorescence intensity measurements for
microvesicles generated from BV-2 and primary microglia. Greater fluorescence intensity
in the resuspended pellet than in the final wash confirms the presence of microvesicles.
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pellet from ATP-treated primary microglia, and from treated and control BV-2 cells. For
the ATP-treated BV-2 cells, the first wash has a fluorescence intensity of 11144, the
second wash is 1465 and the pellet is 3658, 2.5-fold greater. This indicates that the NBD
C6-HPC is embedded in the membranes of the microvesicles in the pellet. The washes
from the control (aCSF-treated) BV-2 microvesicles had intensities of 5984, 899, and the
pellet intensity was 1126. In this case, the pellet has only 25% greater intensity, but that
is still much lower than the first wash, and it seems there fewer microvesicles in the
control pellet than in the pellet from the ATP-treated BV-2 microglia. This representative
result is typical of the microvesicle preparations we have done so far.
5.2 Characterization of microvesicles from primary microglia
Generating microvesicles from primary microglia is challenging because it is
difficult to culture primary microglia in the amounts needed to produce enough
microvesicles to assay. Our primary microglia are in co-culture with astrocytes, so I first
tried using a co-culture of microglia and astrocytes to generate MVs. The data were
promising in that, after using NBD C6-HPC, I was able to detect greater fluorescence
intensity in the microvesicles than in the final wash. However, both the control flask and
the treated flask were not able to be used again after that experiment. New co-cultures
require isolation from mouse pups, so their availability is limited. It is necessary, then, to
use cultures of only primary microglia that are removed from the astrocyte + microglia
co-culture. To isolate primary microglia for experiments, co-culture flasks are shaken for
5 h at 250 rpm. From two T150 (Corning) flasks containing primary murine astrocytes
and microglia, the yield of primary microglia has ranged from 5e4 to 8e5 cells/mL, which
is not even enough to cover one T75 flask to confluence. An additional consideration was
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the viability of the primary microglia seeded in a flask. We had previously plated primary
microglia in 96-well plates for experiments, but I had no experience with primary
microglia monocultures or experimenting on them in a culture flask.
First, I seeded four 25 cm2 flasks with 5x 104 cells/mL in 5 mL and cultured them
for a week, changing the medium twice. The data showed promise, but fluorescence
intensity from the microvesicles was only slightly more intense than 4th wash. However,
from this I confirmed that the primary microglia could be cultured in a flask for at least
one week. Next, 2 T-75 flasks were seeded with 1.6 x 105 cells/mL in 10 mL. After 5
days of culture, with one medium change, these cells were used for a microvesicle
generation experiment. Only 2 washes were done, as seen in Figure 5.5. After this, fewer
co-culture flasks were available, allowing the seeding of just one T-75 flask at a time.
With only one T-75 flask of primary microglia, I did not set up a control (untreated) flask
when generating microvesicles from primary microglia.
The data from an early experiment with primary cells is shown in Figure 5.5. For
microvesicles generated from primary cells, the first wash had an integrated fluorescence
intensity of 8269, the second wash was 842, and the pellet integrated intensity was 1564
– nearly double that of the last wash. Later experiments were done with BzATP, which
has been shown to be more effective at stimulating the P2X7 receptor. Results from those
microvesicle experiments are similar, with about 2-fold greater integrated intensity for
the resuspended pellet than the last wash, indicating the presence of microvesicles.
Following consistent generation of microvesicles from primary microglia, further
investigation would involve experiments in which we treat primary microglia with Ab so
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they internalize it, use BzATP to stimulate microvesicle production, and probe the
microvesicles for Ab using immuno-dot blots and/or ELISAs.
5.3 Overall conclusion
We have shown that surface interaction of Ab with BV-2 microglia produces a
proinflammatory response in the presence protofibrils, but not monomers or fibrils of Ab.
The proinflammatory response, as measured by TNFa secretion, correlated with the time
of exposure to Ab in BV-2 microglia. Primary microglia are much more likely to
internalize SEC-purified protofibrils than monomers, as demonstrated by both time- and
concentration-dependent treatments. SEC separation of Ab monomers and protofibrils is
a strategy that we employ which sets apart our work from the literature on microglial
uptake of Ab and explains differences between our findings and those of other groups.
For instance, we reported that much of the Ab taken up by primary microglia is not
degraded in the lysosomes. We were also able to show that we can generate
microvesicles from BV-2 and primary microglia. Further investigation into whether these
microvesicles can carry internalized Ab back out of microglia is warranted.
The five novel findings from this research include (1) the labeling of a solution of
monomers and protofibrils which are then separated by SEC; (2) protofibrils are
internalized by primary microglia in greater quantities than monomers in both time-and
concentration-dependent experiments; (3) quantitation methods utilizing a plate-reader to
measure uptake of labeled Ab in cells that were treated in a 96-well culture plate; (4) Ab
internalization could not be saturated, even when the concentration of unlabeled Ab was
three-fold greater than labeled Ab; and, (4) contradictory to many reports in the literature,
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a significant amount of internalized Ab was found in the cytoplasm, outside of
lysosomes, and remained stable as protofibrils.
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